Final Program

INTERNATIONAL SYMPOSIUM ON Sjögren’s Syndrome

Chairperson of the Congress: Prof. Salvatore De Vita
Clinic of Rheumatology, University of Udine - Udine, Italy
This course is endorsed by EULAR

Patronages
WELCOME LETTER

It is an honor for Italy to host the “15th International Symposium on Sjögren’s Syndrome”. The Congress comes back to Italy for the second time after the edition held in Venice on December 1999.

The Symposium was proposed on behalf of GRISS (Italian Research Group on Sjögren’s Syndrome) and SIR (Società Italiana di Reumatologia – the Italian Society of Rheumatology), with the hope of encouraging scientific research and interaction especially between younger colleagues, from Italy and from countries abroad.

We are confident that the Symposium will be useful to all attendees, to improve the clinical and scientific progress, to better focus future research and therefore patient care.

The program covers recent developments in pathogenesis, clinical assessment with stratification, lymphoproliferation, and personalized medicine. The discussion will also focus on the nomenclature of Sjögren’s Syndrome and the implications of COVID-19 infection, still present worldwide. The focus is on the evaluation and understanding of the pathogenesis of Sjögren’s Syndrome associated with other autoimmune diseases, and on how different medical specialists and primary care physicians can better coordinate with each other in dealing with patients and in the field of research. The needs and opinions of patients will be another key topic of discussion, with the participation of representatives from European and US Associations, with different health policies applying in different countries. Discussion will be also about recent developments in treatment and testing of new drugs, along with International cooperative research, which is also extremely important.

Welcome everybody to the Symposium and to Rome! We hope this will be a profitable experience and that you will be able to enjoy the Eternal City and this wonderful country!

Salvatore De Vita
Chairperson of the Congress

Luca Quartuccio
Young Co-Chairman

Chiara Baldini
Young Co-Chairman
CHAIRPERSON OF THE CONGRESS
Salvatore De Vita, Italy

YOUNG CO-CHAIRMEN
Chiara Baldini, Italy
Luca Quartuccio, Italy

SCIENTIFIC COMMITTEE
A. Baer, USA
C. Baldini, Italy
E. Bartoloni Bocci, Italy
S. Bombardieri, Italy
M. Bombardieri, UK
H. Bootsma, The Netherlands
S.J. Bowman, UK
L.A. Criswell, USA
S. De Vita, Italy
T. Dörner, Germany
C. Fabro, Italy
R.I. Fox, USA
V. Manfrè, Italy
X. Mariette, France
J.O. Pers, France
L. Quartuccio, Italy
E. Treppo, Italy
A.G. Tzioufas, Greece
A. Zabotti, Italy

LOCAL ORGANIZING COMMITTEE
L. Quartuccio, Italy
A. Zabotti, Italy
E. Treppo, Italy
V. Manfrè, Italy
C. Fabro, Italy
E. Bartoloni Bocci, Italy
F. Conti, Italy
R. Gerli, Italy
R. Priori, Italy
G. Valesini, Italy
C. Vitali, Italy

WORKING TEAM
S. De Vita, Italy
S. Bombardieri, Italy
A.G. Tzioufas, Greece
H. Bootsma, The Netherlands
C. Baldini, Italy
E. Bartoloni Bocci, Italy
M. Bombardieri, UK
M. Ramos-Casals, Spain
T. Dörner, Germany

and consultants
A. Baer, USA
S.J. Bowman, UK
L.A. Criswell, USA
R.I. Fox, USA
X. Mariette, France
J.O. Pers, France

INTERNATIONAL ADVISORY BOARD - PAST PRESIDENTS
A. Baer, USA
S. Bombardieri, Italy
P. Fox, USA
R. Jonsson, Norway
H.M. Moutsopoulos, Greece
A. Parke, USA
J.O. Pers, France
T. Sumida, Japan
A.G. Tzioufas, Greece
P. Youinou, France

INTERNATIONAL COMMITTEE
J.M. Anaya, Colombia
E.K. Akpek, USA
M. Bombardieri, UK
H. Bootsma, The Netherlands
S.J. Bowman, UK
S. Carsons, USA
L.A. Criswell, USA
C.S. De Paiva, USA
T. Dörner, Germany
B.A. Fisher, UK
A.V. Goules, Greece
J.E. Gottenberg, France
S.I. Kwok, Korea
L. Lu, China
X. Mariette, France
T. Mandl, Sweden
C.P. Mavragani, Greece
R. Omdal, Norway
H. Park, Korea
S.C. Plugfelder, USA
M. Ramos-Casals, Spain
S. Retamozo, Spain
L. Ronblom, Sweden
A. Rosen, USA
H.A. Saraux, France
H. Scofield, USA
S.C. Shiboski, USA
M. Tomsic, Slovenia
J. Van Roon, The Netherlands
A. Vissink, The Netherlands
F.B. Vivino, USA
M. Wahren-Herlenius, Sweden
W.F. Ng, UK
<table>
<thead>
<tr>
<th>INDEX</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SCIENTIFIC PROGRAM</td>
<td>P.  7</td>
</tr>
<tr>
<td>Wednesday 7 September</td>
<td>p.  8</td>
</tr>
<tr>
<td>Thursday 8 September</td>
<td>p.  9</td>
</tr>
<tr>
<td>Friday 9 September</td>
<td>p. 14</td>
</tr>
<tr>
<td>Saturday 10 September</td>
<td>P. 20</td>
</tr>
<tr>
<td>NO UEMS SESSIONS</td>
<td>P. 22</td>
</tr>
<tr>
<td>Wednesday 7 September</td>
<td>p. 24</td>
</tr>
<tr>
<td>Saturday 10 September</td>
<td>P. 25</td>
</tr>
<tr>
<td>POSTERS</td>
<td>P. 27</td>
</tr>
<tr>
<td>INFORMATION</td>
<td>P. 49</td>
</tr>
<tr>
<td>TIPS WHEN IN ROME</td>
<td>P. 52</td>
</tr>
<tr>
<td>AUTHORS INDEX</td>
<td>P. 56</td>
</tr>
<tr>
<td>SPONSORS ACKNOWLEDGEMENT</td>
<td>P. 63</td>
</tr>
</tbody>
</table>
S. Francesco Room

14.30–17.45 PRELIMINARY COURSE ULTRASONOGRAPHY OF THE MAJOR SALIVARY GLANDS IN SJÖGREN’S SYNDROME
(see page 24)

Auditorium

18.15-18.30 OPENING CEREMONY
S. De Vita (Italy), S. Bombardieri (Italy), R. Gerli (Italy)

18.30-19.00 MAIN LECTURE
Autoimmunity and infections in marginal zone B-cell lymphomas
M. Ponzoni (Italy)

19.00 Welcome Reception
THURSDAY 8 SEPTEMBER

1. EVOLVING TOPICS IN pSS PATHOGENESIS
Chairs: M. Bombardieri (UK), F.G.M. Kroese (The Netherlands)

08.10-08.20  Properties of epithelial cells
E. Kapsogeorgou (Greece)

08.20-08.30  Infection and the salivary epithelium
M. Wahren-Herlenius (Sweden)

08.30-08.40  Interaction of epithelium with immune cells
G. Nocturne (France)

08.40-08.50  Discussion

08.50-09.08  Innate immunity
M.A. Versnel (The Netherlands)

09.08-09.24  B-cells in benign lesions
G.M. Verstappen (The Netherlands)

09.24-09.42  Autoantibodies
T. Witte (Germany)

09.42-10.10  T cells and co-stimulation
M. Bombardieri (UK)

10.10-10.18  Key findings of genetics and epigenetics
C.J. Lessard (USA)

speaker/chairman remotely connected
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.18-11.07</td>
<td><strong>SELECTED ORAL PRESENTATIONS</strong></td>
</tr>
</tbody>
</table>
| 10.18-10.25 | Long non-coding RNA HCP5 is a key regulator of CDC25 function: implications for Sjögren’s Syndrome  
A. Pinheiro Lopes (The Netherlands) |
| 10.25-10.32 | Transcriptome-wide association study of Sjögren’s disease risk alleles identifies novel genes with altered expression in minor salivary gland and other tissues  
C.J. Lessard (USA) |
| 10.32-10.39 | Single cell and spatial transcriptomics identifies altered cellular neighborhoods in the salivary glands of Sjögren’s disease patients  
W. Blake (USA) |
| 10.39-10.46 | Harnessing cell energy metabolism to suppress salivary gland inflammation in Sjögren’s Syndrome  
S. Colafrancesco (Italy) |
| 10.46-10.53 | Single-cell RNA sequencing data from the sicca collection differentiate Sjögren’s disease and elucidate cellular patterns of composition and expression  
K. Taylor (USA) |
| 10.53-11.00 | Identification of Sjögren’s disease-associated t cell receptors through deep sequencing and single-cell approaches  
A.A. Jupudi (USA) |
| 11.00-11.07 | Baff-Var is a new predisposing factor for pSS and impacts disease activity  
M. Dulin (France) |
| 11.07-11.25 | Coffee break |
THURSDAY 8 SEPTEMBER

2. EVOLVING TOPICS IN pSS STRATIFICATION
Chairs: A. Baer (USA), A.G. Tzioufas (Greece)

The Clinical picture
11.25-11.42  The different clinical phenotypes of pSS
             A.V. Goules (Greece)

Laboratory for stratification
11.42-12.00  Biological markers for stratification in pSS
             J.O. Pers (France)
12.00-12.12  Transcriptomic analysis in different cohorts
             J.E. Gottenberg (France)
12.12-12.24  SICCA NextGen: Preliminary Omics Analyses
             G. Urbanski (USA)

Salivary Imaging and biopsy for stratification
12.24-12.39  Imaging biomarkers for stratification
             C. Baldini (Italy)
12.39-12.51  Labial minor salivary gland biopsy
             B.A. Fisher (UK)
12.51-13.01  Surgical parotid biopsy
             A. Vissink (The Netherlands)
13.01-13.11  US-guided parotid and submandibular biopsy:
             accuracy and safety
             A. Zabotti (Italy)

13.11-14.15  Lunch and Poster tour
The Posters’ Authors are kindly requested to stand by their poster’s
board and be available for discussion
3. EVOLVING TOPICS IN pSS-RELATED LYMPHOPROLIFERATION

Chairs: G. Ferraccioli (Italy), X. Mariette (France)

14.15-14.30 Clinical features of lymphoma updated
A.G. Tzioufas (Greece)

14.30-14.45 The importance of the parotid study in pSS and lymphoma genesis
S. De Vita (Italy)

14.45-15.00 Local networks and oncogenetic events in B cell expansion:
crucial events and perspectives
J. Reed (Australia)

15.00-15.15 Predicting lymphoma in pSS today
X. Mariette (France)

The use of parotid biopsy in pSS...

15.15-15.22 ...for salivary gland swelling or suspect areas
A. Zabotti (Italy)

15.22-15.29 ...for the diagnosis of pSS: YES
T. Dörner (Germany)

15.29-15.36 ...for the diagnosis of pSS: NO
M. Voulgarelis (Greece)

15.36-15.43 ...for both
H. Bootsma (The Netherlands)

15.43-15.50 Discussion

15.50-16.05 Coffee break

16.05-17.15 SELECTED ORAL PRESENTATIONS

16.05-16.12 Cytokine/chemokine expression in primary Sjögren’s Syndrome
patients
L. Chatzis (Greece)

16.12-16.19 Natural history of Sjögren’s disease from the national institutes
of health cohort
B. Law (USA)
THURSDAY 8 SEPTEMBER

16.19-16.26 Transitional CD5+ B cells are associated with autoreactivity in pSS patients
L. Chatzis (Greece)

16.26-16.33 The University of Florida Cohort with childhood Sjögren’s disease classified by the latent class analysis
W. Zeng (USA)

16.33-16.40 Multi-modal analysis supports IL-7/IL-7 receptor axis as a relevant target in Sjögren’s Syndrome
E. Desvaux (France)

16.40-16.47 Symptom-based clustering in Sjögren’s Syndrome: a clue for investigating pathobiological non inflammatory mechanisms of the disease
C. Baldini (Italy)

16.47-16.54 The analysis of macrophage tissue heterogeneity in the salivary glands of patient with primary Sjögren’s Syndrome reveals novel players in the lymphomagenesis of the disorder
M. Manoussakis (Greece)

16.54-17.01 Lymphoma associated risk factors in primary Sjögren’s Syndrome by data driven analysis in harmonized patients
A.V. Goules (Greece)

17.01-17.08 The value of FDG-PET/CT in the detection of lymphomas associated with primary Sjögren’s Syndrome
M.S Van Ginkel (The Netherlands)

17.08-17.15 Value of UHFUS in the diagnostic work up and guided biopsy of suspected labial salivary gland lymphoproliferative lesions in Sjögren’s Syndrome
G. Fulvio (Italy)

speaker/chairman remotely connected
FRIDAY 9 SEPTEMBER

4. EVOLVING TOPICS IN THE EVALUATION OF pSS
Chairs: H. Bootsma (The Netherlands), A.V. Goules (Greece)

Platforms to collect data: built ad hoc or pre-formed/adapted?

08.20-08.28 The Harmonicss experience
T.P. Exarchos (Greece)

08.28-08.36 The Necessity experience
M. Barnes (UK)

08.36-08.40 Discussion

Integration between doctors and engineers using artificial Intelligence

08.40-08.48 The physician point of view
C.P. Mavragani (Greece)

08.48-08.56 The engineer point of view
D.I. Fotiadis (Greece)

08.56-09.00 Discussion on the topic above

09.00-09.20 Activity and damage
H. Bootsma (The Netherlands)

09.20-09.40 Composite indexes and STAR (Sjögren Tool for Assessing Response to treatment) for using in clinical trials
R. Seror (France)

09.40-09.55 Focused clinical endpoints vs. trial endpoints
L. Quartuccio (Italy)

09.55-10.10 Evaluation of the disease-related component of chronic pain and fatigue
W.F. Ng (UK)

speaker/chairman remotely connected
**FRIDAY 9 SEPTEMBER**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.10-10.45</td>
<td>SELECTED ORAL PRESENTATIONS</td>
</tr>
</tbody>
</table>
| 10.10-10.17 | Novel autoantibodies identified in seronegative Sjögren’s using innovative whole peptidome array technology  
S. McCoy (USA) |
| 10.17-10.24 | Identification of a saliva exosomal-RNA signature for Sjögren’s Syndrome  
A. Papas (USA) |
| 10.24-10.31 | Cell type-specific dysregulation found to differentiate patient subsets of Sjögren’s disease  
C.J. Lessard (USA) |
| 10.31-10.38 | The usefulness of ultrasound-guided core needle biopsy of the parotid gland for the diagnosis of primary Sjögren’s Syndrome  
V. Manfrè (Italy) |
| 10.38-10.45 | Ultrasound scoring systems affect the distribution of sialadenitis scores in Sjögren’s Syndrome: an inter-system reproducibility study  
G. Cafaro (Italy) |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.45-11.05</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
### FRIDAY 9 SEPTEMBER

**5. ASSOCIATION OF SS WITH OTHER AUTOIMMUNE DISEASES: IMPLICATIONS FOR DISEASE BIOLOGY AND MANAGEMENT**

*Chairs: T. Dörner (Germany), R. Gerli (Italy)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.05-11.20</td>
<td><strong>pSS, SLE and UCTD</strong></td>
<td>A. Doria (Italy)</td>
</tr>
<tr>
<td>11.20-11.35</td>
<td><strong>pSS with autoimmune thyroid disease or coeliac disease</strong></td>
<td>R. Gerli (Italy)</td>
</tr>
<tr>
<td>11.35-11.50</td>
<td><strong>pSS with SSc</strong></td>
<td>N. Del Papa (Italy)</td>
</tr>
<tr>
<td>11.50-12.05</td>
<td><strong>pSS with RA</strong></td>
<td>G. Nocturne (France)</td>
</tr>
<tr>
<td>12.05-12.16</td>
<td><strong>Polyautoimmunity in Sjögren’s Syndrome</strong></td>
<td>J.M. Anaya Cabrera (Colombia)</td>
</tr>
</tbody>
</table>

#### 12.16-12.30 SELECTED ORAL PRESENTATIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.16-12.23</td>
<td><strong>Single cell Atlas of minor salivary glands reveals key differential cellular and functional players in Sjögren’s and sicca Syndrome</strong></td>
<td>S. Nayar (UK)</td>
</tr>
<tr>
<td>12.23-12.30</td>
<td><strong>Characterization of the muscle inflammatory infiltrate by Hyperion technology in inclusion myositis associated with Sjögren’s Syndrome, comparison with sporadic forms</strong></td>
<td>B. Quéré (France)</td>
</tr>
</tbody>
</table>
FRIDAY 9 SEPTEMBER

6. THE NOMENCLATURE OF SS
Chairs: S. De Vita (Italy), A.G. Tzioufas (Greece)

12.30-12.35  Introduction
A.G. Tzioufas (Greece)

12.35-12.47  Sjögren Syndrome vs Sjögren disease
A. Baer (USA)

12.47-13.00  Secondary vs. Associated Sjögren
P. Brito-Zerón (Spain)

13.00-13.30  Round table with experts and plenary discussion

13.30-14.30  Lunch and Poster tour
The Posters’ Authors are kindly requested to stand by their poster’s board and be available for discussion

7. THE INVOLVEMENT OF DIFFERENT SPECIALITIES IN THE CARE OF SS
Chairs: F. Conti (Italy), J. Barrio Cortes (Spain)

14.30-14.45  New developments in the management of dry mouth
M. Jonsson (Norway)

14.45-15.00  Extraglandular ocular findings of Sjögren’s Syndrome
E.K. Akpek (USA)

Pediatric pSS

15.00-15.15  Clinical manifestations
S. Retamozo (Spain)

15.15-15.30  Recurrent parotitis, US and parotid biopsy in children
A. Tommasini (Italy)

speaker/chairman remotely connected
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30-15.40</td>
<td><strong>seXX matters in Sjögren’s Syndrome</strong></td>
<td>R. Priori (Italy)</td>
</tr>
<tr>
<td>15.40-15.50</td>
<td><strong>Migraine headache and pSS</strong></td>
<td>R.I. Fox (USA)</td>
</tr>
<tr>
<td>15.50-16.00</td>
<td><strong>Concomitant causes of fatigue and chronic pain in pSS</strong></td>
<td>P. Sarzi Puttini (Italy)</td>
</tr>
<tr>
<td>16.00-16.10</td>
<td><strong>Organization of referral pathways in specialized centers</strong></td>
<td>E. Bartoloni Bocci (Italy)</td>
</tr>
<tr>
<td>16.10-16.20</td>
<td><strong>Future improvements proposed by European Rare Disease Network ReCONNECT</strong></td>
<td>M. Mosca (Italy)</td>
</tr>
<tr>
<td><strong>16.20-16.41</strong></td>
<td><strong>SELECTED ORAL PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>16.20-16.27</td>
<td><strong>Outcome of pregnancy in women with primary Sjögren’s Syndrome compared to the general population: the French multicenter prospective GR2 study</strong></td>
<td>G. Frémont (France)</td>
</tr>
<tr>
<td>16.27-16.34</td>
<td><strong>Salivary flow rate and oral status in patients with primary Sjögren Syndrome and diffuse cutaneous systemic sclerosis: a cross-sectional study</strong></td>
<td>M. Radic (Croatia)</td>
</tr>
<tr>
<td>16.34-16.41</td>
<td><strong>Ultra-high frequency ultrasonography of labial glands in pediatric Sjögren’s Syndrome: a preliminary study</strong></td>
<td>E. Marrani (Italy)</td>
</tr>
<tr>
<td><strong>16.41-17.00</strong></td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
</tbody>
</table>
FRIDAY 9 SEPTEMBER

8. pSS AND COVID-19 INFECTION
Chairs: L. Quartuccio (Italy), C. Vitali (Italy)

17.00-17.15  Autoimmunity and COVID-19
M. Galli (Italy)

17.15-17.30  Sjögren’s Syndrome and COVID-19
P. Brito-Zerón (Spain)

17.30-18.20  SELECTED ORAL PRESENTATIONS

17.30-17.37  Safety and efficacy of Sars-Cov-2 vaccination in 1237 patients with primary Sjögren’s Syndrome
N. Inanc (Turkey)

17.37-17.44  Sars-Cov-2 induces a Sjögren’s Syndrome-like phenotype
C. Nguyen (USA)

17.44-17.51  Ianalumab (VAY736) safety and efficacy in patients with Sjögren’s Syndrome: 52 week results from a randomized, placebo-controlled, phase 2b dose-ranging trial
T. Dörner (Germany)

17.51-17.58  Early changes in free light chains to predict ESSDAI, ESSPRI and CRESS and STAR outcomes upon leflunomide/hydroxychloroquine combination therapy
S. Hamkour (The Netherlands)

17.58-18.05  Leflunomide /hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s Syndrome that allow prediction and monitoring of clinical response
S. Hamkour (The Netherlands)

18.05-18.12  In Sjögren’s Syndrome salivary glands Baricitinib downregulates inflammation via a double effect on epithelial cells and inflammatory infiltrates
S. Colafrancesco (Italy)

18.12-18.19  Sjögren’s coexisting with autoimmune diseases: a systematic literature review informing the international task force of Sjögren’s nomenclature and classification Rome 2022
S. Retamozo (Spain)

speaker/chairman remotely connected
9. EVOLVING TOPICS IN pSS THERAPY  
*Chairs: S.J. Bowman (UK), C.H. Shiboski (USA)*

- **08.30-08.50**  
  Current reccomendations and unmet needs  
  M. Ramos-Casals (Spain)

- **08.50-09.05**  
  INPUTS from trials  
  S. Bowman (UK)

- **09.05-09.15**  
  Selection of patients and endpoints for clinical trials  
  S. Arends (The Netherlands)

- **09.15-09.30**  
  Developing novel therapies for patients with Sjögren’s Syndrome: the pharma perspective  
  G. Illei (USA)

- **09.30-10.45**  
  New therapies in the pipeline  
  (see page 25)

- **10.45-11.05**  
  Coffee break

10. EVOLVING TOPICS IN HEALTH POLICIES  
*Chairs: C. Baldini (Italy), S. Bombardieri (Italy)*

- **11.05-11.17**  
  Geographic variation in the management of pSS in Europe  
  C. Seghieri (Italy)

- **11.17-11.29**  
  pSS and the general practitioner  
  J. Barrio Cortes (Spain)

Patients’ needs and health policies

- **11.29-11.41**  
  Sjögren Europe EULAR PARE patient federation?  
  A. Vieira (Portugal)

- **11.41-11.55**  
  SSF USA  
  K.M. Hammitt (USA)

*speaker/chiarman remotely connected*
11. EVOLVING TOPICS IN COOPERATIVE RESEARCH
Chairs: M. Ramos-Casals (Spain), A.G. Tzioufas (Greece)

11.55-12.05    ERN Reconnect
                M. Mosca (Italy)

12.05-12.15    A new multi-center US Sjögren disease research collaboration
                C.H. Shiboski (USA)

12.15-12.25    Big Data
                M. Ramos-Casals (Spain)

12.25-12.35    PRECISESADS
                J.O. Pers (France)

12.35-12.45    HarmonicSS
                A.V. Goules (Greece)

12.45-12.55    Necessity
                X. Mariette (France)

12.55-13.05    Essential
                A.G. Tzioufas (Greece)

13.05-13.15    Sjögren’s Genetics Network (SGENE)
                C.J. Lessard (USA)

13.15-13.45    Closing remarks and Poster Awards
NO UEMS SESSION
**Wednesday 7 September**  
**S. Francesco Room**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30-17.45</td>
<td><strong>PRELIMINARY COURSE ULTRASONOGRAPHY OF THE MAJOR SALIVARY GLANDS IN SJÖGREN’S SYNDROME</strong></td>
</tr>
</tbody>
</table>
| 14.30  | **Introduction and course objectives**  
A. Zabotti (Italy) |
| 14.45-15.00 | **The role of Salivary Gland Ultrasonography (SGUS) in primitive Sjögren’s Syndrome (pSS) patients**  
Chairman: G.A.W. Bruyn (The Netherlands), S. Jousse-Joulin (France) |
| 14.45  | **The role of SGUS in the diagnosis of pSS**  
K. Delli (The Netherlands) |
| 15.00-15.15 | **The role of SGUS in the prognosis and follow-up of pSS**  
C. Baldini (Italy), F. Ferro (Italy) |
| 15.15-15.30 | **The role of SGUS for the differential diagnosis of pSS**  
C. Dejaco (Italy) |
| 15.30-15.45 | **The role of Color Doppler in the SGUS**  
A. Hocevar (Slovenia) |
| 15.45-16.00 | **The sonographic features of lymphoma in pSS patients**  
M. Lorenzon (Italy), I. Giovannini (Italy) |

**Live demonstration**  
Chairman: G.A.W. Bruyn (The Netherlands), S. Jousse-Joulin (France), M. Jonsson (Norway), A. Zabotti (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16.00-16.30 | **Standard scans and normal anatomy of the major salivary glands**  
A. Gattamelata (Italy), L. Navarini (Italy) |
| 16.30-17.30 | **Hands on in pSS patients**  
Supervisors: A. Gattamelata (Italy), L. Navarini (Italy), K. Delli (The Netherlands), A. Stel (The Netherlands) |
| 17.30-17.45 | **Take home messages**  
A. Zabotti (Italy)**

**NO UEMS SESSIONS**
Saturday 10 September  

**NEW THERAPIES IN THE PIPELINE**

**09.30-10.45**

09.30-09.45  Horizon Therapeutics: Moving Science Forward for Rare, Autoimmune and Severe Inflammatory Diseases  
I. Alevizos (USA)

09.45-10.00 Reduction of Sjögren’s autoantibodies by blocking IgG recycling through the neonatal Fc Receptor (FcRN)  
K. Sivils (USA)

10.00-10.45 Discussion
Please note that the abstract book is ordered by topic and the numbering corresponds to the submission ID, while the numbering of the posters in the final program follows the poster board number. Please refer to the title of the abstract to look for the entire text of the work.
1. EVOLVING TOPICS IN pSS PATHOGENESIS

**PO1:01** EXPLORATION OF THE CELLULAR MICROENVIRONMENT IN MINOR SALIVARY GLANDS OF PATIENTS WITH PRIMARY SJÖGREN´S SYNDROME BY IMAGING MASS CYTOMETRY


Bergen, Norway

**PO1:02** CCL5 RELEASE BY CCR9+ CD8 T CELLS: A POTENTIAL NOVEL CONTRIBUTOR TO IMMUNOPATHOLOGY OF PRIMARY SJÖGREN´S SYNDROME

Hinrichs A., Blokland S., Kruize A., Lafeber F., Leavis H., Van Roon J.*

Utrecht, The Netherlands

**PO1:03** B CELL GLYCOSYLATION IN PRIMARY SJÖGREN´S SYNDROME: A NEW POTENTIAL BIOMARKER.


Brest, France

**PO1:04** PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN A COHORT OF PRIMARY SJÖGREN´S SYNDROME: A NOVEL MARKER OF DISEASE ACTIVITY?

Cafaro G.*, Bianconi V., Perricone C., Cosentini E., Riccucci I., Mannarino M.R., Pirro M., Gerli R., Bartoloni E.

Perugia, Italy

**PO1:05** DECIPHERING THE ROLE OF CDC2S IN SJÖGREN´S SYNDROME: TRANSCRIPTOMIC PROFILE LINKS ALTERED ANTIGEN PROCESSES WITH IFN-SIGNATURE AND AUTOIMMUNITY


Utrecht, The Netherlands

**PO1:06** SINGLE CELL RNA SEQUENCING POINTS TO A ROLE FOR FIBROBLASTS EARLY IN SALIVARY GLAND DYSFUNCTION IN PRIMARY SJÖGREN´S SYNDROME

Pringle S.* Berg M., Spijkervet F., Vissink A., Bootsma H., Kroese F.G.M.

Groningen, The Netherlands

**PO1:07** ABNORMALITIES OF EXTRACELLULAR MATRIX MODELING GENE EXPRESSION IN SALIVARY GLAND EPITHELIAL CELLS OF PATIENTS WITH SJÖGREN´S SYNDROME

Rivière E.*, Pascaud J., Letourneur F., Nocturne G., Mariette X.

Paris, France

**PO1:08** DEFECTIVE LOCALIZATION AND INTERACTION OF AQUAPORIN-5 INTERACTING PROTEIN PARTNERS IN SALIVARY GLANDS FROM PATIENTS WITH PRIMARY SJÖGREN´S SYNDROME

D’Agostino C.*1, Chivasso C.1, Filipovic N.1, Conrad L.1, Zindy E.1, Perret J.1, Muhammad S.S.1, Moscato S.2, Baldini C.2, Mattii L.2, Delporte C.1

1Bruxelles, Belgium, 2Pisa, Italy
**POSTER**

**PO1:09** EXPLORATORY IMMUNOPHENOTYPE OF THE RARE DISEASE JUVENILE SJÖGREN’S SYNDROME REVEALS A DYSREGULATION OF B AND T MEMORY CELL FREQUENCIES.

**PO1:10** IMMUNE CHECKPOINT INHIBITOR TREATMENT MAY INDUCE SALIVARY GLAND PROGENITOR CELL PROLIFERATION
Pringle S.*, Van Der Vegt B., Vissink A., Bootsma H., Kroese F.G.M. Groningen, The Netherlands

**PO1:11** FINE MAPPING OF THE DDX6-CXCR5 RISK INTERVAL REVEALS SNPS IN SJÖGREN’S DISEASE WITH FUNCTIONAL SIGNIFICANCE IN IMMUNE CELLS AND SALIVARY GLAND
Wiley M.1, Khatri B.1, Tessneer K.1, Joachims M.1, Stolarczyk A.1, Nagel A.1, Rasmussen A.1, Bowman S.J.2, Radfar L.1, Omdal R.3, Wahren-Herlenius M.4, Warner B.5, Witte T.6, Jonsson R.7, Rischmüller M.8, Gaffney P.1, James J.A.1, Rönnblom L.9, Scofield R.H.1, Mariette X.10, Ng W.F.11, Sivils K.12, Nordmark G.9, Tsao B.13, Lessard C.J.11
1Oklahoma City, USA, 2 Birmingham, UK 3 Stavanger, Norway, 4 Stockholm, Sweden, 5 Bethesda USA, 6 Hannover, Germany, 7 Bergen, Norway, 8 Adelaide, Australia, 9 Uppsala, Sweden, 10 Le Kremlin Bicêtre, France, 11 Newcastle Upon Tyne, UK, 12 Spring House, USA, 13 Charleston, USA

**PO1:12** CYTOKINE MRNA DETECTION IN SALIVARY GLANDS OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME USING THE RNASCONE® ISH TECHNOLOGY
Borge H.*1, Fromreide S.1, Aqrawi A.L.2, Dongre H.1, Galtung H.2, Liaaen Jensen J.2, Skarstein K.1
1Bergen, Norway, 2 Oslo, Norway

**PO1:13** LABIAL AND PAROTID SALIVARY GLAND HISTOPATHOLOGY IN PRIMARY SJÖGREN’S SYNDROME

**PO1:14** USE OF SALIVARY AUTOANTIBODIES IN SICCA PATIENTS TO DETECT DISEASE
Tsiliki M.*, Cavett J., Kurien B., Bruxvoort C., Scofield R.H., Koelsch K.A. Oklahoma City, USA

**PO1:15** M6A METHYLATION OF RNA IN SALIVARY GLAND EPITHELIAL CELLS: ROLE IN SJÖGREN’S SYNDROME
Shalabi H., Rivière E., Pascaud J., Nocturne G., Mariette X., Bechara R.* Le Kremlin Bicêtre, France

**PO1:16** ABNORMALITY OF TYPE I INTERFERON SIGNALLING IN B CELLS IN PRIMARY SJÖGREN’S SYNDROME AND THE IMPACT ON LABORATORY AND CLINICAL FINDINGS
**POSTER**

**P01:17 IMMUNIZATION IN PRIMARY SJÖGREN’S SYNDROME - THE IMPORTANCE OF THE CYTOKINE PROFILE IN RESPONSE TO DISEASE-MODIFYING THERAPY**
Wrocław, Poland

**P01:18 SSA-REACTIVE B CELLS ESCAPE PERIPHERAL TOLERANCE CHECKPOINTS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME**
Chriti N., Tison A., Porchet E., Marec N., Devauchelle-Pensec V., Pers J.O., Hillion S., Corne D.*
Brest, France

**P01:19 TARGETED METABOLOMICS IN LABIAL SALIVARY GLANDS HIGHLIGHTS NEW POTENTIAL BIOMARKERS TO PREDICT PRIMARY SJÖGREN’S SYNDROME.**
Urbanski G.*1, Chabrun F.1, Lacout C.1, Lozac H.P.2, Blanchet O.1, Chao De La Barca J.1, Simard G.1, Lavigne C.1, Reynier P.1
1Angers, France, 2Le Mans, France

**P01:20 THE TUBARIAL GLANDS RESEMBLE THE PALATAL SALIVARY GLANDS BASED ON FURTHER HISTOLOGICAL CHARACTERIZATION, AND MAY REPRESENT AN ORGAN OF INTEREST IN PRIMARY SJÖGREN’S SYNDROME**
Pringle S.*1, Bikker F.2, Vogel W.2, Hofland I.2, Van Der Vegt B.1, Bootsma H.1, Kroese F.G.M.1, Vissink A.1, Valstar M.2
1Groningen, The Netherlands, 2Amsterdam, The Netherlands

**P01:21 DOES ANCESTRY INFLUENCE PRIMARY SJÖGREN’S SYNDROME PHENOTYPE OR SEVERITY?**
Beydon M.*1, Seror R.1, Desmoulins F.1, Mariette X.2, Nocturne G.1
1Paris, France, 2Le Kremlin Bicêtre, France

**P01:22 CCR9/CXCR5 CO-EXPRESSING CD4 T CELLS ARE INCREASED IN PRIMARY SJÖGREN’S SYNDROME AND ENRICHED IN PD-1/ICOS EXPRESSING EFFECTOR T CELLS**
Hinrichs A., Leavis H., Kruize A., Lafeber F., Van Roon J.*
Utrecht, The Netherlands

**P01:23 IL-1 ALPHA AND IL-1 BETA EXPRESSION IN PRIMARY SJÖGREN’S SYNDROME SALIVARY GLAND EPITHELIAL CELLS**
1Rome, Italy

**P01:24 IDENTIFYING POTENTIAL PATHOGENIC MECHANISMS IN PRIMARY SJÖGREN’S SYNDROME USING METABOLOMICS AND MACHINE LEARNING APPROACHES**
Martin-Gutierrez L.*, Zhang S., Peng J., Robinson G., Butt M., Ciurtin C., Jury E.
London, UK
PO1:26 MITOCHONDRIAL DYSFUNCTION IN SJÖGREN’S SYNDROME
Kurien B.T.*, Pharaoh G., Cavett J., Lewis V., Chambers A., Bhaskaran S., Anjum J.,
Karfonta B., Radfar L., Rasmussen A., Lessard C.J., Farris A.D., Sivils K., Koelsch K.A.,
Van Remmen H., Scofield R.H.
Oklahoma City, USA

PO1:27 INVOLVEMENT OF INTERFERON IN THE PATHOPHYSIOLOGY OF VAGINAL DRYNESS
IN PRIMARY SJÖGREN’S SYNDROME.
Visser A.*, Nimwegen J., Bootsma H., Van Der Tuuk K., Mourits M., Van Kempen L.,
Kroese F.G.M., Verstappen G.
Groningen, The Netherlands

PO1:28 DEEP SPATIAL PROFILING OF SJÖGREN SYNDROME PATIENTS BY IMAGING MASS
CYTOMETRY: PRELIMINARY RESULTS
1 Athens, Greece, 2, Brest, France

PO1:30 TLR7 REGULATES X-LINKED TLR ADAPTOR ENDOlysosomal SLC15A4 (TASL)
EXPRESSION IN SJÖGREN’S DISEASE SUBJECTS
Harris-Lewis V.*, Bruxvoort C., Lawrence S., Cavett J., Kurien B., Scofield R.H.
Oklahoma City, USA

PO1:31 REGULATION OF STAT4 EXPRESSION BY GROWTH FACTOR SUPPLEMENTATION IN
SJÖGREN’S SYNDROME CELL CULTURE MODELS
Mougeot J.*, Noll B., Thornburg T., Noll J., Cathleen P., Lizano M., Brennan M., Mougeot F.
Charlotte, USA

PO1:32 AUTOPHAGY-RELATED PRDM1-ATG5 RISK LOCUS IN SJÖGREN’S DISEASE
Nagel A.1, Khatri B.1, Radziszewski M.1, Wiley M.1, Stolarczyk A.1, Joachims M.1, Tessneer K.1,
Rasmussen A.1, Bowman S.J.2, Radfar L.1, Omdal R.3, Wahren-Herlenius M.4, Warner B.5,
Witte T.6, Jonsson R.7, Rischmueller M.8, Gaffney P.1, James J.A.1, Rönnblom L.9, Scofield R.H.1,
Mariette X.10, Alarcón-Riquelme M.E.11, Ng W.F.12, Nordmark G.9, Farris A.D.1, Lessard C.J.*1
1 Oklahoma City, USA, 2 Birmingham, UK, 3 Stavanger, Norway, 4 Stavanger, Norway, 5 Bethesda,
USA, 6 Hannover, Germany, 7 Bergen, Norway, 8 Adelaide, Australia, 9 Uppsala, Sweden, 10 Le
Kremlin Bicêtre, France, 11 Granada, Spain, 12 Newcastle Upon Tyne, UK

PO1:34 ELEVATED LEVELS OF IL-9 FAIL TO SUPPRESS PATHOGENIC TH17 CELLS IN
SJÖGREN’S SYNDROME
Voigt A.*, Shen Y., Nguyen C.
Gainesville, USA
PO1:35 UNIQUE BIOLOGICAL PROFILE OF GERMINAL CENTRES WITHIN TERTIARY LYMPHOID STRUCTURES IN THE SALIVARY GLANDS OF PATIENTS WITH SJÖGREN’S SYNDROME
Nayar S.*1, Turner J.D.1, Asam S.1, Colfrancesco S.2, Berardicurti O.3, Iannizzotto V.1, Smith C.1, Flint J.1, Teodósio A.1, Gardner D.H.1, Bowman S.J.1, Ng W.F.4, Croft A.P.1, Filer A.1, Fisher B.A.1, Buckley C.D.5, Barone F.6
1Birmingham, UK, 2Rome, Italy, 3L’Aquila, Italy, 4Newcastle upon Tyne, UK, 5Oxford, UK, 6Massachusetts, USA

PO1:36 ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) AUTOANTIBODIES AS POTENTIAL BIOMARKER OF FATIGUE IN PATIENTS WITH SJÖGREN SYNDROME
Marinoska T.*1, Möckel T.2, Dreher M.2, Schwarting A.2
1Bad Kreuznach, Germany, 2Mainz, Germany

PO1:37 ONSET OF PAROTID SWELLING AND SUBSEQUENT PRIMARY SJÖGREN’S SYNDROME AFTER RUBELLA VACCINE
Manfrè V.*1, Fabro C., Longhino S., Rizzo M.T., Giovannini I., Pegolo E., Zabotti A., Quartuccio L., De Vita S.
Udine, Italy

PO1:38 ANALYSIS OF IFN-REGULATED CHEMOKINES AND B CELL SUBSETS IN PEDIATRIC SJÖGREN’S SYNDROME
Boni A., Pires Marafon D., Caiello I., Matteo V., Marasco E.*, Prencipe G., Nicolai R., Bracaglia C., De Benedetti F.
Rome, Italy

2. EOLVING TOPICS IN pSS STRATIFICATION

PO2:39 ALTERED CELL FREQUENCIES IN PATIENTS WITH SJÖGREN’S SYNDROME
Bergen, Norway

PO2:40 SJÖGREN’S AND NON-SJÖGREN’S SICCA SHARE A SIMILAR SYMPTOM BURDEN BUT WITH A DISTINCT SYMPTOM-ASSOCIATED PROTEOMIC SIGNATURE
Pucino V.*1, Jason D.T.1, Nayar S.1, Florian K.2, Rauz S.1, Richards A.1, Poveda-Gallego A.1, Higham J.1, Bowman S.J.1, Barone F.3, Fisher B.A.1
1Birmingham, UK, 2Bern, Switzerland, UK, 3Boston, USA

PO2:41 SYSTEMIC INVOLVEMENT IN SJÖGREN SYNDROME: CAN WE PREDICT IT?
Bandeira M.*, Silvério António M., Khmelinskii N., Eurico Fonseca J., Romão V.C.
Lisbon, Portugal

PO2:42 AUTOANTIBODIES AGAINST AQUAPORIN-5 IN PRIMARY SJÖGREN SYNDROME AS POTENTIAL DISEASE ACTIVITY AND PROGNOSTIC BIOMARKER.
Stano S.*
Bari, Italy
PO2:43 ANTI-SSA/RO PROFILING IN PATIENTS WITH NEWLY DIAGNOSIS OF SJÖGREN SYNDROME: IMPACT ON “SICCA” AND “NON-SICCA” DISEASE ONSET
Fonzetti S.*, Ferro F., Fulvio G., La Rocca G., Navarro Garcia I.C., Donati V., Mosca M., Baldini C. Pisa, Italy

PO2:44 SJÖGREN’S SYNDROME ILD PREVALENCE AND ASSOCIATED RISK FACTORS, A MONOCENTRIC COHORT STUDY
La Rocca G.*, Ferro F., Fulvio G., Fonzetti S., Navarro I., Elefante E., Mosca M., Baldini C. Pisa, Italy

PO2:45 COMPREHENSIVE ANALYSIS OF CLINICAL AND LABORATORY FEATURES OF 440 PUBLISHED CASES OF PRIMARY SJÖGREN’S SYNDROME AND RENAL TUBULAR ACIDOSIS
Sandhya P.* Delhi, India

PO2:46 JUVENILE PRIMARY SJÖGREN SYNDROME – CLINICAL INSIGHTS
Rajão Martins F.*, Aguiar F.2, Rodrigues M.2, Brito I.2
1Faro, Portugal, 2Porto, Portugal

PO2:47 CHARACTERIZATION OF SEROPOSITIVE AND SERONEGATIVE SJÖGREN’S SYNDROME ACCORDING TO THE 2016 ACR/EULAR CLASSIFICATION CRITERIA
Longhino S.*, Manfré V., Rizzo M.T., De Vita S., Quartuccio L. Udine, Italy

PO2:48 WHAT DOES ISOLATED ANTI-RO52 ANTIBODY POSITIVITY MEAN IN SJÖGREN’S SYNDROME?
Bettacchioli E.*, Saraux A.1, Tison A.1, Cornec D.1, Dueymes M.1, Alarcón-Riquelme M.E.2, Devauchelle-Pensec V.1
1Brest, France, 2Granada, Spain

PO2:49 PALPABLE PURPURA ASSOCIATED RISK FACTORS IN PRIMARY SJÖGREN’S SYNDROME BY DATA DRIVEN ANALYSIS IN HARMONIZED PATIENTS.
1 Athens, Greece, 2Ioannina, Greece, 3Udine, Italy, 4Thessaloniki, Greece, 5Darmstadt, Germany, 6Madrid, Spain, 7Hannover, Germany, 8Kragujevac, Greece, 9Heraklion, Greece, 10Pisa, Italy, 11London, UK, 12Groningen, The Netherlands, 13Birmingham, UK, 14Brussels Belgium, 15Brest, France, 16Berlin, Germany, 17Perugia, Italy, 18L’Aquila, Italy, 19Bergen, Norway, 20Newcastle upon Tyne, UK, 21Rome, Italy, 22Barcelona, Spain, 23Oklahoma, USA, 24Utrecht, The Netherlands, 25Paris, France
P02:51 COLOR DOPPLER ASSESSMENT OF SALIVARY GLANDS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
Giovannini I.*1, Manfrè V.1, Hocevar A.2, Quartuccio L.1, De Vita S.1, Zabotti A.1
1 Udine, Italy, 2 Ljubljana, Slovenia

P02:52 TOP LINE RESULTS FROM NPRODNAP0017: A DIRECT-TO-PATIENT LONGITUDINAL STUDY FOR DIGITAL AND BIOMARKER DISEASE PROFILING OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND SJÖGREN’S SYNDROME (PSS)
Avey S.*1, Reynoso E.1, Hu X.1, Ven K.2, Pandis I.3, Bonet D.1, Lontoc T.1, Patel C.1, Mosca K.1, Liu G.1, Morris M.1, Murphy P.3, Franks C.1, Leszczuk J.1
1 Spring House, USA, 2 Beerse, Belgium, 3 London, UK

P02:53 DIAGNOSTIC VALUE OF MONOSPECIFIC ANTI-DFS70 ANTIBODIES IN PRIMARY SJÖGREN’S SYNDROME
Khvan Y.*, Torgashina A., Chaltsev B., Verizhnikova Z.
Moscow, Russian Federation

3. EVOLVING TOPICS IN pSS - RELATED LYMPHOPROLIFERATION

P03:54 EARLY DETECTION OF MALT LYMPHOMA IN SJÖGREN’S SYNDROME PATIENTS THROUGH IMMUNOGENETICS
Rotterdam, The Netherlands

P03:55 CHARACTERISTICS, PREDICTIVE AND PROGNOSIS FACTORS OF RELAPSE OR DEATH FOR NON-HODGKIN LYMPHOMAS IN PRIMARY SJÖGREN SYNDROME
Rocca J.1, Beydon M.1, Le Guern V.2, Hachulla E.3, Dubost J.J.4, Jousse-Joulin S.5, Devauchelle-Pensec V.5, Gottenberg J.E.6, Vittecoq O.7, Lavigne C.8, Schmidt J.9, Marcelli C.10, Larroche C.11, Mariette X.1, Nocturne G.1*, Seror R.1
1 Le Kremlin Bicêtre, France, 2 Paris, France, 3 Lille, France, 4 Clermont Ferrand, France, 5 Brest, France, 6 Strasbourg, France, 7 Rouen, France, 8 Angers, France, 9 Amiens, France, 10 Caen, France

P03:56 HIGHER LYMPHOMA RISK IN SJÖGREN’S SYNDROME IN THE NORTH EAST OF ITALY OVER 15 YEARS OF FOLLOW-UP: THE FIRST ITALIAN STUDY MATCHING THE CANCER REGISTRY AND THE ADMINISTRATIVE DATABASE
Treppo E.*1, Toffolini F.2, Manfrè V.1, Taborelli M.2, De Vita S.1, Serraino D.2, Quartuccio L.1
1 Udine, Italy, 2 Aviano, Italy

P03:57 THE COURSE OF PRIMARY SJÖGREN’S SYNDROME PRIOR TO THE DEVELOPMENT OF LYMPHOMA: SHOULD SYSTEMIC THERAPY BE USED IN THE TREATMENT OF GLANDULAR FORMS OF THE DISEASE?
Chaltsev B., Vasiliev V., Torgashina A., Khvan Y., Sokol E.*
Moscow, Russian Federation
PO3:58 MARGINAL ZONE LYMPHOMAS IN PRIMARY AND SECONDARY SJÖGREN’S SYNDROME
Moscow, Russian Federation

PO3:60 SALIVARY GLAND ULTRASONOGRAPHY IN MALT LYMPHOMA COMPPLICATING SJÖGREN’S SYNDROME: DYNAMIC CHANGES AFTER IMMUNOSUPPRESSIVE TREATMENT
Torgashina A.*, Chaltsev B., Khvan Y.
Moscow, Russian Federation

PO3:61 UNCERTAIN DIAGNOSIS OF MALT LYMPHOMA IN SJÖGREN’S SYNDROME: THE POSSIBLE ROLE OF CENTROCYTE-LIKE CELL CONFLUENCE AND B-CELL CLONALITY FOR A BETTER STRATIFICATION
Longhino S.*, Scott C.A., Fabro C., Quartuccio L., De Vita S.
Udine, Italy

PO3:62 LYMPHADENOPATHY IN SJÖGREN SYNDROME
Athens, Greece, Ioannina, Greece, Pisa, Italy

PO3:63 EXPRESSION OF MIR-155 IN SALIVARY GLANDS TISSUE OF PRIMARY SJÖGREN’S SYNDROME: CORRELATION WITH DISEASE CHARACTERISTICS AND LYMPHOPROLIFERATIVE EVOLUTION
Bruno D.*, Di Mario C., Paglionico A., Varriano V., Ferraccioli G., Tolusso B., Alivernini S., Gremese E.
Rome, Italy

PO3:64 PREDICTING LYMPHOMA IN PRIMARY SJÖGREN’S SYNDROME: THE ROLE OF PRECISE PAROTID SWELLING RECORDING
Udine, Italy, Pisa, Italy, Athens, Greece, Trieste, Italy, Ioannina, Greece, Milan, Italy

PO3:66 EFFICACY OF RITUXIMAB ON CLINICAL, HISTOLOGICAL, IMMUNOHISTOCHEMICAL AND MOLECULAR CHARACTERISTICS OF MALT-LYMPHOMA IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME.
Chaltsev B.*, Torgashina A., Khvan Y.
Moscow, Russian Federation
4. EVOLVING TOPICS IN THE EVALUATION OF pSS

P04:67 HOW TO EVALUATE ULTRASOUND ABNORMALITIES OF SALIVARY GLANDS IN SJÖGREN SYNDROME USING WEB TRAINING SESSION DURING COVID 19 PERIOD? AN INTERNATIONAL RELIABILITY EXERCISE
Quéré B.1, Saraux A.1, Carvajal Alegria G.2, Guellec D.1, Mouterde G.3, Lamotte C.4, Hammenfors D.5, Jonsson M.5, Sung-Eun C.6, Hong-Ki M.7, Stel A.8, Fisher B.A.9, Hofauer B.10, Ferro F.12, Milic V.11, Direnzo D.13, Devauchelle-Pensec V.1, Jousse-Joulin S.1
1Brest, France, 2Tours, France, 3Montpellier, France, 4Lille, France, 5Bergen, Norway, 6Gwangju, Korea, Republic of Korea, 7Seoul, Korea, Republic of Korea, 8Groningen, The Netherlands, 9Birmingham, UK, 10Freiburg, Germany, 11Belgrade, Serbia, 12Pisa, Italy, 13Philadelphia, USA

P04:68 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME IN DAILY CLINICAL PRACTICE
Groningen, The Netherlands

P04:69 ASSOCIATION BETWEEN SALIVARY SCINTIGRAPHIC AND HISTOPATHOLOGIC DATA OF MINOR SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME
Han J.H.*, Kim J., Roh J., Kim H.
Suwon, Korea, Republic of Korea

P04:70 COMPARISON BETWEEN PRIMARY SJÖGREN’S SYNDROME PATIENTS WITH AND WITHOUT DRYNESS
Kachaner A.1, Mariette X.2, Desmoulins F.2, Nocturne G.2, Seror R.2
1Paris, France, 2Kremlin Bicêtre, France

P04:71 THE COURSE OF JUVENILE ONSET SJÖGREN’S SYNDROME
Vasiliev V., Palshina S., Shornikova L.*, Rodionova E., Novikov A.
Moscow, Russian Federation

P04:72 AUTOMATIC QUANTIFICATION OF DRY EYE BY ARTIFICIAL INTELLIGENCE IN THE CONTEXT OF SJÖGREN’S SYNDROME
Brahim I.*, Lamard M., Ben-Youssef A., Conze P., Cochner-Lamard B., Quellec G., Corne C. D.
Brest, France

P04:73 SALIVARY GLAND ULTRASONOGRAPHY (SGUS) IN PRIMARY SJÖGREN’S SYNDROME AS MARKER OF DISEASE SEVERITY AND ITS ASSOCIATIONS WITH CLINICAL CHARACTERISTICS, ESSDAI AND ESSPRI AND SALIVARY PROTEOMICS.
Bisaralli R., Rath P.D., Nanda R., Sahu A.K., Chouhan S.
New Delhi, India

P04:74 AUTONOMIC DYSFUNCTION IN SJÖGREN’S DISEASE
Fenando A.1, Estes J.1, Shah S.1, Lee J.1, Jabari D.1, Baker J.2, Noaiseh G.*1
1Kansas City, USA, 2Philadelphia, USA
PO4:75 DRY EYE SYMPTOMS STRONGLY CORRELATE WITH OCULAR AND EXTRAOCULAR PAIN IN PRIMARY SJÖGREN’S SYNDROME. INTERIM REPORT OF A PILOT CROSS-SECTIONAL MONOCENTRIC STUDY.
Moroni L., Ferrari G., Bonelli F., Batani V.*, Bellone M., Dagna L.
Milan, Italy

PO4:76 ECOLOGICAL MOMENTARY ASSESSMENT OF THE SYMPTOMS IN SJÖGREN’S SYNDROME: DEVELOPMENT AND VALIDATION OF A DEDICATED WEBAPP
Georgel L.¹, Berrouiguet S.¹, Ben-Youssef A.¹, Guellec D.¹, Carvajal Alegria G.², Marhadour T.¹, Jousse-Joulin S.¹, Cochener B.¹, Labetouille M.³, Saraux A.¹, Graye M.¹, Devauchelle-Pensec V.¹, Seror R.³, Cornc D.*¹
¹Brest, France, ²Tours, France, ³Kremlin-Bicêtre, France

PO4:77 IN-DEPTH ANALYSIS OF SALIVARY GLAND BIOPSIIES: DEVELOPMENT OF NEW TOOLS USING HYPERION MASS CYTOMETRY TO ACCURATELY DETERMINE SJÖGREN’S SEVERITY STATUS
Scuiller Y.*, Foulquier N., Hemon P., Pers J.O., Jamin C.
Brest, France

PO4:78 INFLUENCE OF EPIDEMIOLOGY AND ETHNICITY ON SYSTEMIC EXPRESSION OF PRIMARY SJÖGREN SYNDROME AT DIAGNOSIS: WORLDWIDE PATTERNS IN 14,836 PATIENTS (2022 SJÖGREN BIG DATA PROJECT)
¹Barcelona, Spain, ²Debrecen, Hungary, ³Hefei, Anhui, China, ⁴Oklahoma, USA, ⁵Newcastle upon Tyne, UK, ⁶Beijing, China, ⁷Rome, Italy, ⁸Malmö, Sweden, ⁹Pisa, Italy, ¹⁰Paris, France, ¹¹Groningen, The Netherlands, ¹²Ankara, Turkey, ¹³Ciudad de Mexico, Mexico, ¹⁴Strasbourg, France, ¹⁵Utrecht, The Netherlands, ¹⁶Ljubljana, Slovenia, ¹⁷Tamil Nadu, India, ¹⁸Ankara, Turkey, ¹⁹Istanbul, Turkey, ²⁰Udine, Italy, ²¹Wrocław, Poland, ²²Perugia, Italy, ²³Lisboa, Portugal, ²⁴Adelaide, Australia, ²⁵Kanazawa, Japan, ²⁶Seoul, Korea, Republic of Korea, ²⁷Stockholm, Sweden, ²⁸Barcelona, Spain, ²⁹São Paulo, Brazil, ³⁰Paris, France, ³¹São Paulo, Brazil, ³²London, UK, ³³Munich, Germany, ³⁴Nagasaki, Japan, ³⁵Uppsala, Sweden, ³⁶Vitoria, Espírito Santo, Brazil, ³⁷Bucharest, Romania, ³⁸L’Aquila, Italy, ³⁹Madrid, Spain, ⁴⁰Brest, France, ⁴¹Madrid, Spain, ⁴²Cairo, Egypt, ⁴³Barcelona, Spain, ⁴⁴Tarragona, Spain, ⁴⁵Asturias, Spain, ⁴⁶Madrid, Spain, ⁴⁷Montpellier, France, ⁴⁸Rome, Italy, ⁴⁹Milan, Italy, ⁵⁰Montevideo, Uruguay, ⁵¹San Lorenzo, Paraguay, ⁵²Madrid, Spain, ⁵³Barcelona, Spain
PO4:79 ESSPRI REFLECTS COMMON SYMPTOMS OF PRIMARY SJÖGREN’S SYNDROME BETTER THAN ESSDAI
Ilgen U.1, Erol Kalkan K.2, Ademoglu Z.3, Hakan E.3
1Bitlis, Turkey, 2Istanbul, Turkey, 3Edirne, Turkey

PO4:81 SERUM BETAZ-MICROGLOBULIN AS A MARKER OF ACTIVE PRIMARY SJÖGREN’S SYNDROME AND EXTRAGLANDULAR INVOLVEMENT
Bueno I.B.*, Oliveira M.C., Oliveira F.R.
Ribeirão Preto, Brazil

PO4:82 ULTRASONOGRAPHY OF LACRIMAL GLANDS: UNDERESTIMATE TOOL IN PRIMARY SJÖGREN’S SYNDROME. A CASE REPORT
Giovannini I.1, Zandonella Callegher S.2, Longhino S.*1, Manfrè V.1, De Vita S.1, Zabotti A.1
1Udine, Italy, 2Brunico, Italy

PO4:83 VALIDITY OF THE NOVEL OMERACT ULTRASOUND SCORING SYSTEM FOR SALIVARY GLANDS TARGET LESIONS IN SJÖGREN’S SYNDROME
Inanc N.*1, Jousse-Joulin S.2, Abacar K.1, Cimsit Ç.1, Cimsit C.1, D’Agostino M.3, Naredo E.4, Hocevar A.5, Finzel S.6, Terslev L.7, Pineda C.8, Keen H.9, Iagnocco A.10, Hanova P.11, Schmidt W.A.12, Mumcu G.1, Bruyn G.A.W.13
1Istanbul, Turkey, 2Brest, France, 3Versailles, France, 4Madrid, Spain, 5Ljubljana, Slovenia, 6Freiburg, Germany, 7Copenhagen, Denmark, 8Ciudad de México, Mexico, 9Perth, Australia, 10Turin, Italy, 11Prague, Czech Republic, 12Berlin, Germany, 13Lelystad, The Netherlands

PO4:84 ULTRASOUND EVALUATION OF MAJOR SALIVARY GLANDS IN AN ITALIAN COHORT OF PRIMARY SJÖGREN’S SYNDROME PATIENTS: A MONOCENTRIC STUDY
Rome, Italy

PO4:86 COMPREHENSIVE ASSESSMENT OF PATIENTS WITH SUSPECTED SJÖGREN’S SYNDROME: 5-YEAR RESULTS OF A MULTIDISCIPLINARY SJÖGREN’S SYNDROME CLINIC
Lisbon, Portugal

PO4:87 NOVEL AUTOANTIBODIES IDENTIFY SJÖGREN’S DISEASE IN PATIENTS LACKING SERUM IGG SPECIFIC FOR RO/SS-A AND LA/SS-B
Oklahoma City, USA
P04:88 DOES EULAR SJÖGREN’S SYNDROME PATIENT REPORTED INDEX (ESSPRI)-PAIN MODERATE DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME?
Yenisoy Y.1, Altingöz E.N.1, Kapusuz A.1, Abacar K.Y.1, Tatli I.1, Türe-Özdemir F.1, Karacayli U.2, Yay M.1, Direskeneli H.1, Fortune F.3, Inanc N.*1, Mumcu G.1
1Istanbul, Turkey, 2Ankara, Turkey, 3London, UK

P04:89 POSTURAL TACHYCARDIA AND SJÖGREN DISEASE
Goodman B.*, Arca K.
Scottsdale, USA

P04:90 THE SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR): ASSESSMENT OF RESPONSE RATES OVERALL, ACCORDING TO BASELINE ACTIVITY AND BY DOMAIN: REANALYSIS OF 9 CLINICAL TRIALS IN PRIMARY SJÖGREN’S SYNDROME
Seror R.*1, Baron G.1, Cornec D.2, Perrodeau E.1, Camus M.1, Bowman S.J.3, Bombardieri M.4, Bootsma H.5, Arends S.5, Gottenberg J.E.6, Fisher B.A.7, Hueber W.8, Roon J.V.9, Devauchelle-Pensec V.2, De Wolff L.8, Gergely P.8, Mariette X.1, Porcher R.1

P04:91 COMPARISON OF ULTRASOUND AND SIALOGRAPHY OF MAJOR SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME
Khvan Y.*, Torgashina A., Chaltsev B.
Moscow, Russian Federation

P04:92 ULTRASOUND OF SALIVARY GLANDS IN PATIENTS WITH POSITIVE AND NEGATIVE ANTICENTROMERE ANTIBODIES PRIMARY SJÖGREN’S SYNDROME
Khvan Y., Torgashina A., Chaltsev B.*
Moscow, Russian Federation

P04:94 CASE SERIES OF EXTRAGLANDULAR MANIFESTATIONS OF PRIMARY SJÖGREN SYNDROME IN A UNIVERSITY HOSPITAL OF BOGOTÁ, COLOMBIA.
Borda Samper C.*, Navarrete Motta L.E., Bernal Macías S., Fernández Ávila D.G., Diaz M.C., Gutierrez Davila J.M., González Rojas B.J.
Bogotá, Colombia
5. ASSOCIATION OF SS WITH OTHER DISEASES: IMPLICATIONS IN DISEASE BIOLOGY AND MANAGEMENT

PO5:95 SEX HORMONES AND RELATED COMORBIDITIES ARE ASSOCIATED WITH DEVELOPING SJÖGREN’S DISEASE: A POPULATION-BASED NESTED CASE-CONTROL STUDY
Mccoy S.*1, Hetzel S.1, Vanwormer J.2, Bartels C.1
1Madison, USA, 2 Marshfield, USA

PO5:97 MALIGNANCIES AMONG PATIENTS WITH SJÖGREN’S SYNDROME
Szántó A.*, Aradi Z., Orosz V.
Debrecen, Hungary

PO5:98 SALIVARY GLANDS ULTRASONOGRAPHY VALUE IN RHEUMATOID ARTHRITIS PATIENTS WITH DRY SYNDROME
Brest, France

PO5:99 SIGNIFICANCE OF RHEUMATOID FACTOR ISOYTOPES IN PATIENTS WITH SJÖGREN’S SYNDROME WITH JOINT COMPLAINTS OF DIFFERENT ETIOLOGY
Aradi Z.*, Nagy G., Szántó A.
Debrecen, Hungary

PO5:100 MYOSITIS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: DATA FROM A FRENCH NATIONWIDE SURVEY
Houssais C.1, Noury J.1, Allenbach Y.2, Gallay L.3, Quéré B.*1, Assan E.4, Benveniste O.2, Broner J.5, Duffau P.6, Espitia A.7, Grasland A.8, Sanges S.9, Hachulla E.9, Hayem G.4, Le Guern V.10, Martis N.11, Mariampillai K.2, Mulleman D.12, Nocturne G.13, Mariette X.13, Meyer A.14, Devauchelle-Pensec V.1, Cornec D.1, Guellec D.1
1Brét, France, 2Paris, France, 3Lyon, France, 4Boulogne-Billancourt, France, 5Nimes, France, 6 Bordeaux, France, 7Nantes, France, 8Colombes, France, 9Lille, France, 10Paris, France, 11Nice, France, 12 Tours, France, 13 Kremlin-Bicêtre, France, 14 Strasbourg, France

PO5:101 PRIMARY SJÖGREN’S SYNDROME PRESENTING AS THROMBOTIC THROMBOCYTOPENIC PURPURA IN A MALE PATIENT WITH PREVIOUS KIKUCHI-FUJIMOTO DISEASE
Silvério António M., Alves Ribeiro L., Medeiros J., Romão V.C.*, Fonseca J.E.
Lisbon, Portugal

PO5:102 CHARACTERIZATION OF THE ASSOCIATION BETWEEN PRIMARY SJÖGREN’S SYNDROME AND SYSTEMIC LUPUS ERITEMATOSUS (PSS/SLE)
De Marchi G.1, Chiara B.2, Elefante E.2, Manfrè V.1, Navarro I.2, Giovannini I.1, Treppo E.1, Zabotti A.1, Quartuccio L.1*, De Vita S.1, Longhino S.1
1Udine, Italy, 2Pisa, Italy
PO5:103 CLINICAL AND HISTOLOGICAL FEATURES OF PATIENTS WITH PRIMARY SJÖGREN SYNDROME AND AUTOIMMUNE THYROIDITIS: A NATIONAL MULTICENTRIC CROSS-SECTIONAL STUDY
Celia A.I.*1, Colafrancesco S.1, Villa M.1, Gattamelata A.1, Izzo R.1, Giardina F.1, Simoncelli E.1, Mastromanno L.1, Baldini C.2, Bartolini E.3, Carubbi F.4, Quartuccio L.5, Orlandi M.6, Gerli R.3, Giacomelli R.7, De Vita S.5, Alessandri C.1, Conti F.1, Priori R.7
1 Rome, Italy, 2 Pisa, Italy, 3 Perugia, Italy, 4 L’Aquila, Italy, 5 Udine, Italy, 6 Florence, Italy, 7 Rome, Italy

PO5:104 IMMUNOPATHOLOGICAL SCENARIOS DEFINING COEXISTENCE BETWEEN SJÖGREN SYNDROME AND SARCOIDOSIS
1 Barcelona, Spain, 2 UK, 3 Istanbul, Turkey, 4 Avezzano-Sulmona-L’Aquila, Italy, 5 Sabadell, Spain, 6 Paris, France, 7 Brest, France, 8 Germany, 9 São Paulo, Brazil, 10 Madrid, Spain, 11 Barcelona, Spain, 12 Tarragona, Spain, 13 Lisboa, Portugal, 14 Ciudad de Mexico, Mexico

PO5:105 HIGH PREVALENCE OF SJÖGREN’S SYNDROME AMONG PRIMARY IMMUNODEFICIENCIES: A STUDY IN A TERTIARY CENTER OF NORTH-EASTERN ITALY
Longhino S., De Marchi G., Fabro C., Rizzo M.T.*, Manfrè V., Quartuccio L., De Vita S.
Udine, Italy

PO5:106 RESPIRATORY PATTERNS IN PATIENTS WITH SJÖGREN’S SYNDROME AND POSTURAL TACHYCARDIA
Arca K.*, Goodman B.
Scottsdale, USA

PO5:107 COMPARISON OF SALIVARY EXOSOMAL-RNA IN SJÖGREN’S, RHEUMATOID ARTHRITIS AND LUPUS
Singh M.*2, Sawicki B.1, Chakrabortty S.1, Cole J.1, Lang S.1, Yu S.1, Johan S.1, Papas A.2
1 Waltham, USA, 2 Boston, USA

PO5:108 FEATURES OF JOINT MANIFESTATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN COMBINATION WITH SJÖGREN’S SYNDROME.
Torgashina A.*, Matianova E., Gordeev A.
Moscow, Russian Federation

PO5:109 EVALUATION OF SOME IMMUNOLOGICAL MARKERS IN RHEUMATOID ARTHRITIS IN COMBINATION WITH SJÖGREN’S DISEASE.
Torgashina A.*, Matianova E.
Moscow, Russian Federation
7. INVOLVEMENT OF DIFFERENT SPECIALITIES IN THE CARE OF SS

P07:111 DISTINGUISHING CHILDHOOD SJÖGREN’S DISEASE IN PATIENTS PRESENTING WITH SIALADENITIS TO A PEDIATRIC MULTIDISCIPLINARY OTOLARYNGOLOGY/RHEUMATOLOGY CLINIC
Holley A.*, Park A., Stern S.
Salt Lake City, USA

P07:112 MULTI-SPECIALTY COLLABORATION IN DEVELOPMENT OF GUIDELINES FOR MANAGEMENT OF NEUROLOGICAL MANIFESTATIONS OF SJÖGREN’S DISEASE
1Reston, USA, 2La Jolla, USA, 3Philadelphia, USA, 4Stanford, USA, 5Boston, USA, 6Moore, USA, 7Phoenix, USA, 8Northwell, New York, USA, 9Kansas City, USA, 10New York, USA, 11Los Angeles, USA, 12Saint Louis, USA, 13Beverly Hills, USA, 14Oklahoma City, USA, 15Mineaola, USA, 16San Francisco, USA

P07:113 NEW INSIGHT INTO OCULAR SURFACE DYSFUNCTION IN SJÖGREN SYNDROME.
Moawad P., Hassanein D., Shamma R., El Zawahry O., Ragab G.*
Cairo, Egypt

P07:114 CULTURAL ADAPTATION AND PRELIMINARY VALIDATION OF THE QUALISEX QUESTIONNAIRE FOR ITS USE IN PATIENTS WITH SJÖGREN’S SYNDROME
Villa M.*1, Giardina F., Gioia C., Iannuccelli C., Gattamelata A., Colafrancesco S., Mastromanno L., Simoncelli E., Conti F., Di Franco M., Currano G., Priori R.
1Rome, Italy, 2L’Aquila, Italy

P07:115 HEARING DYSFUNCTION IN SJÖGREN’S SYNDROME
Rome, Italy

P07:116 ADHERENCE TO THE MEDITERRANEAN DIET IN ITALIAN WOMEN WITH PRIMARY SJÖGREN’S SYNDROME
Rome, Italy

P07:117 PHYSICAL ACTIVITY LEVEL IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
1Vitória, Brazil, 2Ribeirão Preto, Brazil
P07:118 IMPACT OF SJÖGREN’S SYNDROME ON OCCUPATIONAL PERFORMANCE AND QUALITY OF LIFE
Cintra B.C.*, Marzola M.M., Carretta R.Y.D., Rocha E.M., Oliveira F.R. 
Ribeirão Preto, Brazil

P07:119 NEUROPSYCHIATRIC SJÖGREN SYNDROME: AN ATYPICAL MANIFESTATION OFENCEPHALITIS A CASE REPORT
Navarrete Motta L.E.*, Ramírez J., Gutiérrez J.M., Díaz M.C., Fernández Ávila D.G., 
García Alfonso C., Bernal Macias S. 
Bogotá, Colombia

P07:122 UPDATE ON RADIOGRAPHIC EVIDENCE OF IMPLANT THERAPY IN SJÖGREN’S PATIENTS
Laing Gibbard L.*, Lee J. 
Toronto, Canada

8. pSS AND COVID-19 INFECTION

P08:123 A SINGLE-CENTER COVID VACCINATION EXPERIENCE IN PATIENTS WITH SJÖGREN’S SYNDROME
Horvath I.F.*, Nagy B., Barath S., Orosz V., Szántó A. 
Debrecen, Hungary

P08:124 MODEL IMMUNIZATION WITH CORONAVIRUS-2 VACCINES INDUCE POTENT ANTIBODY RESPONSES BUT DOES NOT AGGRAVATE LYMPHOCYTE ABNORMALITIES IN PRIMARY SJÖGREN’S SYNDROME PATIENTS
Groningen, The Netherlands

P08:125 IMMUNOGENICITY AND SAFETY OF CHADOX1 NCOV-19 VACCINE IN PRIMARY SJÖGREN’S SYNDROME.
Libardi Lira Machado K.L.1, Oliveira Souza B.1, Barbosa Beloni Lírio M.1, Neves Burian A.P.1, 
Gonçalves Rodrigues De Aguiar L.1, Smith Sobral Vieira G.1, Ribeiro Moulaz I.1, 
Gomes M.D.P.1, Tatiama Miyamoto S.1, Vieira Serrano E.1, Reis Neto E.2, 
Teixeira-Carvalho A.2, Valim V.*1, Monticielo O.A.2, De Souza V.A.2, Ferreira G.A.2, 
Inoue Sato E.? Xavier R.2, Salviato Pillegi G.2, Mill J.G.1, Assis Martins-Filho O.3 
1Vitória, Brazil, 2 São Paulo, Brazil, 3Belo Horizonte, Brazil
**POSTER**

**P08:126 SARS-COV-2 INFECTION IN 898 PATIENTS WITH SJÖGREN’S SYNDROME: CHARACTERISTICS ASSOCIATED WITH POOR OUTCOMES**
¹Barcelona, Spain, ²San Francisco, USA, ³Lisboa, Portugal, ⁴Ankara, Turkey, ⁵Paris, France, ⁶Madrid, Spain, ⁷L’Aquila, Italy, ⁸Roma, Italy, ⁹Manchester, UK, ¹⁰Berlin, Germany, ¹¹Boston, USA, ¹²San Francisco, USA, ¹³Hamilton, Canada, ¹⁴USA, ¹⁵St. Paul, MN, USA, ¹⁶New York, USA, ¹⁷Otago Wellington, New Zealand, ¹⁸Massachusetts, USA, ¹⁹London, UK, ²⁰Vitoria, Brazil

---

**9. EVOLVING TOPICS IN pSS THERAPY**

**P09:127 METFORMIN IMPROVES OBJECTIVE MEASURES OF DRY EYES AND FOCUS SCORE IN SJÖGREN’S DISEASE: A RETROSPECTIVE OBSERVATIONAL STUDY**
Rasmussen A.*, Scofield R.H., Grundahl K., Radfar L., Lessard C.J., Farris A.D.
Oklahoma City, USA

**P09:128 SAFETY AND TOLERABILITY OF NIPOCALIMAB ADMINISTERED AT DIFFERENT RATES OF INTRAVENOUS INFUSION IN HEALTHY ADULTS: A PHASE 1 PLACEBO-CONTROLLED SINGLE-DOSE STUDY**
Leu J.H.,¹ Vermeulen A.,² Zazzetti F.*,³, Ling L.E.⁴
¹Spring House, USA, ²Beerse, Belgium, ³Buenos Aires, Argentina, ⁴Cambridge, USA

**P09:129 DESIGN OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN ANTAGONIST, IN ADULTS WITH PRIMARY SJÖGREN’S SYNDROME**
Hubbard J.*,¹ Campbell K.,¹ Sivils K.,¹ Hoffman R.W.,¹ Lo K.H.,¹ Leu J.H.,¹ Liva S.G.,¹ Zuraw Q.,¹ Stevens A.M.,¹ Berhanu A.,¹ Scofield R.H.,¹ Seror R.,² Wallace D.J.³
¹Spring House, USA, ²Paris, France, ³Los Angeles, USA, ⁴Oklahoma City, USA

**P09:130 DYNAMICS OF US-CHANGES IN THE STRUCTURE OF SALIVARY GLANDS WITH CYCLOPHOSPHAMIDE THERAPY DURING ONE YEAR IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME**
Khvan Y.*, Torgashina A., Chaltsev B., Vasiliev V.
Moscow, Russian Federation

**P09:131 USE OF PLATELET-RICH PLASMA (PRP) IN TREATMENT OF DRY EYE SYNDROME IN THE PATIENTS WITH SJÖGREN SYNDROME: PRELIMINARY RESULTS**
Capacci A., Rubortone P., Ricci F., D’Agostino M.
Rome, Italy

**P09:132 QUALITY OF LIFE IN PATIENTS WITH SJÖGREN’S DISEASE TAKING SIALAGOGUES**
Sankar V.*, Pagni S., Singh M., Hammitt K.M., Makara M., Papas A.
¹Boston, USA, ²Reston, USA
PO09:133 INTERFERON ASSOCIATED PROTEINS FOR MONITORING AND PREDICTION OF CLINICAL RESPONSE TO LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY DEFINED BY COMPOSITE ENDPOINTS (PRELIMINARY) STAR AND CRESS
Bogers C.*1, Hamkour S.1, Blokland S.1, Versnel M.A.2, Leavis H.1, Van Roon J.1
1Utrecht, The Netherlands, 2Rotterdam, The Netherlands

PO09:134 EFFECTS OF SIALAGOGUES TREATMENT IN SJÖGREN’S DISEASE PATIENTS
Khoury Z.*1, Pagni S.1, Sankar V.1, Singh M.1, Makara M.2, Hammitt K.M.2, Papas A.1
1Boston, USA, 2Reston, USA

PO09:135 PATIENT SATISFACTION AND IMPACT OF SALIVARY FLOW ON EFFECTIVENESS OF XEROSTOMIA PRODUCTS: PATIENT CENTERED APPROACH FOR THE MANAGEMENT OF XEROSTOMIA
Brennan M.*1, Purdie J.1, Stephens C.1, Taylor Y.1, Hammitt K.M.2, Napenas J.1, Noll J.1
1Charlotte, USA, 2Reston, USA

PO09:136 PERSONALIZED MEDICINE IN TREATING SJÖGREN’S SYNDROME BY TARGETING AUTOANTIGENIC EPITOPES AND HLA-DRB1*0301 ALLELE INTERACTION
Gupta S.*, Nguyen C.
Gainesville, USA

PO09:137 AQP1 GENE THERAPY CORRECTS FLUID SECRETION DEFICITS IN SJÖGREN’S DISEASE
Perez P.1, Warner B.1, Ji Y.1, Afione S.1, Pranzatelli T.1, Beach M.1, Khavandgar Z.1, Grissius M.1, Pelayo E.1, Baer A.2, Chiorini J.*1
1Bethesda, USA, 2Baltimore, USA

PO09:138 RITUXIMAB PREVENTS WORSENING OF B-CELL DRIVEN SALIVARY GLAND INFLAMMATION AND EXCRETORY FUNCTION IN PRIMARY SJÖGREN’S SYNDROME: RESULTS FROM THE TRACTISS TRIAL
Pontarini E.*1, Chowdhury F.1, Sciacca E.1, Grigoriadou S.1, Emery P.2, Ng W.F.3, Sutcliffe N.1, Rivellese F.1, Tappuni A.1, Lucchesi D.1, Seror R.4, Xavier M.4, Porcher R.5, De Wolff L.6, Arends S.7, Bootsma H.6, Lewis M.1, Pitzalis C.1, Bowman S.J.7, Bombardieri M.1

10. EVOLVING TOPICS IN HEALTH POLICIES

PO10:139 HOW RARE IS PRIMARY SJÖGREN SYNDROME?
Chevet B.*1, Chiche L.2, Devauchelle-Pensec V.1, Cornec D.1
1Brest, France, 2Marseille, France
POSTER

11. EVOLVING TOPICS IN COOPERATIVE RESEARCH

PO11:140 A DIAGNOSTIC ALGORITHM FOR EVALUATING CHILDHOOD SJÖGREN’S DISEASE
Stern S.M.*4, Basiaga M.L.1, Cha S.2, Thaatayikom A.3, Treemarcki E.B.4, Randell R.5,
Dizon B.L.6, Dilommi J.7, Tiger S.7, Orrock J.E.8, Appenzzeller S.9, Edens C.10, Lieberman S.M.11
1Rochester, USA, 2Gainesville, USA, 3Orlando, USA, 4Salt Lake City, USA, 5Durham, USA,
6Bethesda, USA, 7Broomall, USA, 8Austin, USA, 9Campinas, Brazil, 10Chicago, USA, 11Iowa City,
USA

PO11:141 KEY FEATURES AT DIAGNOSIS OF PRIMARY SJÖGREN SYNDROME IN 15,652 PATIENTS: 2022 SJÖGREN BIG DATA PROJECT
Flores-Chavez A.*5, Fanny Horváth I.17, Li X.18, Rasmussen A.19, Ng W.F.1, Dong X.20,
Kruize A.26, Hernandez-Molina G.27, Paprovnik S.27, Danda D.28, O¨zkiziltas B.28, Inanc N.29,
Sebastian A.30, Bartoloni Bocci E.30, Quartuccio L.31, Romao V.C.32, Rischmueller M.33, Suzuki Y.34,
Kwok S.35, Kvarnstrom M.36, Solans R.5, Pasato S.G.37, Galisteo C.5, Sene D.34, Moça Trevisani V.37,
Isenberg D.38, Hofauer B.10, Shimizu T.38, Nordmark G.40, Valim V.41, Jurcut C.4, Carubbi F.42,
González García A.12, Retamozo S.5, Devauchelle-Pensec V.11, Melchor Diaz S.12,
Gheita T.A.3, Brito-Zerón P.5, López-Dupla M.43, Fonseca-Aizpuru E.44, Sanchez Berna I.12,
Morel J.13, Giaccomelli R.42, Atzeni F.14, Consani S.15, Vázquez M.16, Akasbi M.12
1UK, 2The Netherlands, 3Cairo, Egypt, 4Bucharest, Romania, 5Barcelona, Spain, 6Strasbourg,
France, 7Ljubljana, Slovenia, 8Ankara, Turkey, 9Wroclaw, Poland, 10Rechts der Isar, Germany,
11Brest, France, 12Madrid, Spain, 13Montpellier, France, 14Milan, Italy, 15Montevideo, Uruguay,
16San Lorenzo, Paraguay, 17Debrecen, Hungary, 18Hefei, Anhui, China, 19USA, 20Beijing, China,
21Rome, Italy, 22Malmö, Sweden, 23Pisa, Italy, 24Paris, France, 25Ankara, Turkey, 26Utrecht,
The Netherlands, 27Ciudad de Mexico, Mexico, 28Tamil Nadu, India, 29Istanbul, Turkey, 30Perugia,
Italy, 31Undine, Italy, 32Lisbon, Portugal, 33Adelaide, Australia, 34Kanazawa, Japan, 35South
Korea, Korea, Republic of Korea, 36Stockholm, Sweden, 37São Paulo, Brazil, 38London, UK,
39Nagasaki, Japan, 40Uppsala, Sweden, 41Vitoria, Brazil, 42L’Aquila, Italy, 43Tarragona, Spain,
44Asturias, Spain

PO11:142 CD4+ CYTOTOXIC T LYMPHOCYTES (CTL) ARE PRESENT IN SJÖGREN’S DISEASE MINOR SALIVARY GLANDS AND ASSOCIATE WITH MARKERS OF EPITHELIAL CELL DAMAGE NEAR INFILTRATES
Joachims M.1, Li C.1, Rusbultd J.2, Fowler B.1, Rasmussen A.1, Grundahl K.1, Scofield R.H.1,
Sivis K.2, Lessard C.J.1, Farris A.D.*1
1Oklahoma City, USA, 2Spring House, USA

PO11:143 PERSONALITY TRAITS CORRELATE WITH DISEASE ACTIVITY IN PRIMARY SJÖGREN’S SYNDROME
Debrecen, Hungary
12. MISCELLANEOUS

PO12:144 WORLD SJÖGREN’S DAY 2021: A 3-AXIS CAMPAIGN ABOUT FATIGUE
Grosjean A.*, Stone L., Vieira A., Koelewijn-Tukker J., Bouillot C., Antonopoulou K., Oosterbaan M. Bienne, Switzerland

PO12:149 IMPACT OF NEUROLOGICAL COMPLICATIONS ON QUALITY OF LIFE IN SJÖGREN’S
Church J.E.*, Makara M., Hammitt K.M. Reston, USA

PO12:150 PERCEPTIONS, BEHAVIORS AND EXPERIENCES RELATED TO COVID-19 AND THE
COVID-19 VACCINE: A SURVEY OF U.S.-BASED SJÖGREN’S PATIENTS
Makara M.*, Church J.E., Hammitt K.M. Reston, USA

PO12:151 UNMET NEEDS IN RESEARCH, HOW PATIENTS CAN COLLABORATE: THE
EXAMPLE OF NECESSITY
Bouillot C.*,1, Hammitt K.M.2, Hjertviksten Lindland A.3, Oosterbaan M.4, Pincemin M.1, Stone L.5
1Paris, France, 2Reston, USA, 3Oslo, Norway, 4Maarssen, The Netherlands, 5Birmingham, UK

PO12:152 AN EMPIRICAL LINGUISTIC ANALYSIS OF THE TERMS USED FOR THE DISEASE
DESCRIBED BY HENRIK SJÖGREN
Yarowsky D.1, Mackey A.2, Turner B.1, Blanck J.1, Hammitt K.M.3, Ramos-Casals M.4, Baer A.*1
1Baltimore, MD, USA, 2Washington, DC, USA, 3Reston, VA, USA, 4Barcelona, Spain

PO12:153 RECIPROCAL IMPACT OF FIBROMYALGIA ON DISEASE CHARACTERISTICS AND
PHYSICAL AND PSYCHOLOGICAL DOMAINS IN SJÖGREN SYNDROME: CROSS SECTIONAL
OBSERVATIONAL STUDY.
Capacci A.*, Rubortone P., Alivernini S., D’Agostino M. Rome, Italy

PO12:155 DIAGNOSTIC UTILITY OF A SECOND MINOR SALIVARY GLAND BIOPSY IN
PATIENTS WITH SUSPECTED SJÖGREN’S SYNDROME: A RETROSPECTIVE COHORT STUDY
Carvajal Alegria G.*, Depinoy T., Devauchelle-Pensec V., Jousse-Joulin S., Marhadour T., Guellec D., Marcorelles P., Pers J.O., Saraux A., Corne D. Brest, France

PO12:156 SJÖGREN’S AND NON-SJÖGREN SICCA IN TIMES OF CORONA
Baert-Jansen A.*, Koelewijn-Tukker J., Visser-Noordegraaf M. Maarssen, The Netherlands

PO12:157 PATIENT ASSOCIATION IN TIMES OF CORONA
CONGRESS PLATFORM AND VIRTUAL ACCESS
Being an hybrid event, all the sessions of the Sjögren’s Symposium are live streamed through the platform https://sjogrensymposium.livebit.it
For the first access you will be required to enter the access code received by the Organizing Secretariat. For further log-in please create your own username and password. A chat with the Organizing Secretariat in the platform is available for assistance.

ABSTRACT BOOK
All submitted abstracts, accepted as oral presentation or poster, have been published in the Abstract Book of the Congress, in the special edition of the Clinical and Experimental Rheumatology Journal. The abstract book is available for download from the Congress website https://www.sjogren2022.com/

GUIDELINES FOR CHAIRPERSONS AND SPEAKERS
• Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session to meet each other
• Respect the timing allowed to the session and to each presentation
• All presentations, discussions and questions must be in English

Audiovisual instructions
Speakers are requested to submit their presentations (16:9 format) to the slide centre at least 2 hour before the start of their session. Personal computers cannot be connected to the projectors in the session room and presentations cannot be loaded directly on the computer of the session rooms. If speakers created their presentation using a system different from Windows (such as OS MAC or Linux), they are kindly requested to provide presentations in a Windows-compatible format and to come earlier to the slide centre, in order to have enough time to solve possible compatibility issues. At the slide centre our hostess will welcome and help speakers. Experienced technicians will assist speakers in transferring the slides and make changes if needed. Slide presentations will then be uploaded to the Auditorium.

BEST PAPERS
The best posters presented will receive a prize during the Closing Ceremony. The selection will be done by the Chairs during sessions

ORAL COMMUNICATIONS
Participants presenting in oral sessions are requested to submit their presentations to the slide centre at least 2 hour before the start of their session.

CME ACCREDITATION
An application has been made to the EACCME® for CME accreditation of this event. Attendance is monitored through a scanner device to check learner’s entrance/exit each day. Attending 100% of the sessions is a main requirement to obtain credits. Participants will receive their certificate of attendance and UEMS credit points certificate once they have filled in the evaluation form through an online system. All the information will be sent by e-mail after the congress by the Organizing Secretariat. Make sure we have your most updated email address at the Registration desk.
GENERAL INFORMATION

CONGRESS VENUE
Auditorium Antonianum
Viale Manzoni 1 – Rome (Italy)
It is located few steps away from the San Giovanni in Laterano Cathedral and the Colosseum, close to the metro-line station Manzoni and 15 min far by walking from the train station Termini.

ORGANIZING SECRETARIAT
AIM Group International – Milan Office
Via G. Ripamonti, 129 – 20141 Milan, Italy

SECRETARIAT AND REGISTRATION DESK
The on-site registration desks will be open during the following days:
• Wednesday September 7, hrs 13.30-19.00
• Thursday September 8, hrs 07.30-17.30
• Friday September 9, hrs 07.30-18.30
• Saturday September 10, hrs 08.00-14.00

ADMISSION
Participants are kindly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, coffee breaks and lunches.

OPENING CEREMONY AND WELCOME COCKTAIL
The Opening Ceremony of the Congress will be held on September 7 from hrs 18.15 in the Auditorium of the Congress Venue. A standing cocktail will follow.

COFFEE BREAKS AND LUNCHES
Coffee breaks and buffet lunches are included in the registration fee. They are served at level 1, in the congress venue.

SOCIAL DINNER
The Social Dinner (upon payment) will be held on September 9, hrs 20.00, at the Les Etoiles Restaurant. It is a panoramic restaurant located at the last floor of the Hotel Atlante, close to the Vatican district.
Address: Via Giovanni Vitelleschi, 34 – 00193 Rome.
If you paid for your seat, do not forget to pick up the invitation card at the Registration Desk. Transfer to/from the Social Dinner venue is not provided. Info on how to reach the Restaurant are available at the Registration Desk.

LANGUAGE
The official language is English. No simultaneous translation will be provided.
GENERAL INFORMATION

CUSTOMER SATISFACTION SURVEY & CERTIFICATE OF ATTENDANCE
At the end of the event, you will receive an online survey to score the main congress services. This will help us doing better in the future. Your attendance certificate will be ready for download at the end of the survey.

SAFETY MEASURES
The Organizing Secretariat is strongly committed to deliver the safest in presence event and is constantly monitoring the global health situation. Conference spaces are suitable to host safely all registered attendees and do comply with current public health guidance. The Organizing Secretariat Staff will constantly check the flows in the congress area to avoid any crowding.

For everyone’s safety, we kindly invite all delegates to wear face masks in all conference spaces.

Hand sanitizing units are placed throughout the venue.

We are committed to ensure you get the most out of your Congress experience in a safe environment.

CLOAKROOM
Cloakroom and luggage storage facilities are available in the Congress venue

WI-FI
Free Wi-Fi is available in the Congress area. Please connect to the network Auditorium Antonianum and enter the password Sjogren2022!

NO-SMOKING
Smoking in the meeting area is not allowed.

MOBILE PHONES
Delegates are kindly requested to set their mobile phones on silent mode in the Auditorium where scientific sessions are being held.

INSURANCE
Congress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.

PRIVACY POLICY
The information on the processing of personal data in accordance with European Regulation nr. 679 of 2016 has been inserted in the Congress bags. Please consult the information sheet for full details.
TIPS WHEN IN ROME
TIPS WHEN IN ROME

Here’s what you need to know when visiting Rome

**Order coffee at the bar**

Order your coffee directly at the bar to avoid paying a service charge for being served at a table, which often doubles your bill. When you enter a café, locate the cashier and place your order, then take your receipt to the bar to receive your beverage of choice. Espresso only takes a minute to enjoy so it’s easy to drink it standing up.

P.S Don’t order a cappuccino after noon: avoid committing one of Italy’s most infamous food crimes and enjoy your frothy cappuccino before noon. Cappuccino is only suitable at breakfast (preferably paired with a cornetto, an Italian croissant). Hint: a caffè macchiato, an espresso with a splash of milk, is an acceptable alternative that you can order at any hour of the day without raising any eyebrows.

**Gelato is acceptable any time, any season**

Italy’s longstanding customs and traditions can be difficult to navigate, but you don’t have to worry about eating gelato in the colder months. Italians enjoy this treat year-round and Rome’s best artisanal gelaterie change their flavours seasonally, so look out for juicy fruit flavours and interesting combinations with pistachios and hazelnuts.

**Get your stomach on Roman time**

Lunch between 13-14.
Aperitivo between 17-19.
Restaurants open for dinner from 19.30 – occasionally 19.00. They’ll really start to fill up around 20.30-21.00.

Rome is absolutely packed with delicious food, but if you’re looking for the most traditional pastas in Rome, look no further than the four dishes: carbonara, pasta alla gricia, amatriciana, and cacio& pepe are all sublime.

Don’t consider your trip to Rome complete unless you’ve at least sampled a few bites of each!
TIPS WHEN IN ROME

**Tipping is not obligatory, but it’s appreciated**

Tipping has not traditionally been part of the Italian culture, as service charge is generally included in the bill as the coperto (cover) or breadbasket but leaving a few extra coins at the table is often appreciated. Depending on the final price of your meal, the level of service you received and the number of people in your party, you can leave anywhere from 5-10% on the table. Italy still largely functions on a cash economy, so be sure to carry cash with you during your time in Rome. Coins, or spicci, are especially welcome at cafés small shops so hold on to your Euros – they’re a precious commodity here.

**Buy bus tickets ahead of time**

Rome’s public transportation leaves much to be desired, but if you need to take a bus in the city centre, be sure to stock up on bus tickets ahead of time because you can’t buy them on the bus. You can buy tickets at any tabaccheria in the city, little convenient shops that are designated with a large T. Tickets are €1.50 each, or opt for a 24-hour, 48-hour or weekly ticket for a discounted price. Tickets are valid for all forms of public transportation in Rome (bus, metro, tram and local train).

**Watch your bags**

Always be mindful of your bags on public transportation and around key tourist attractions (this is a general rule that you should use in any crowded, large city anyway). The city is very safe but petty crime is rampant, especially on crowded buses and metros. Thieves in Rome are stealthy, so always keep your bags zipped and held in front of you; wallets should ideally be tucked in your inner jacket pockets. Never leave a bag hanging off a chair at a restaurant.

**Dress modestly in church**

Rome has over 900 churches that house some of the city’s most beautiful works of art, so don’t miss stepping inside to marvel at their treasures, whether you’re devout or not. Just be sure to dress appropriately to enter these holy spaces: women’s shoulders should be covered, and skirts should hit at or below the knee, while men should wear pants or shorts that extend to the knees. Linen pants are a great option for the summer and a scarf is a perfect last-minute cover-up if you’re wearing a tank top.
### TIPS WHEN IN ROME

**Don’t try to see the Vatican Museums and Colosseum on the same day**
It’s an absolutely exhausting endeavor, and won’t leave time for seeing much of anything else that day in Rome!

**Book tickets and tours for popular attractions in advance**
It requires a bit of extra planning but honestly makes for a better experience, too.

**How to say…**

When you enter a shop or a restaurant you can say “buongiorno” until lunchtime and “buonasera” in the afternoon and evening; when you leave, you should say “arrivederci.”

Grazie = thank you
Per favore = please
Prego = you’re welcome

When you need your bill at the restaurant just stay at the table and say to the waiter “Mi porta il conto per favore?”
A
Aarebrot A.K. 32
Abacar K.Y. 39, 41
Abma A. 47
Ademoglu Z. 38
Afione S. 45
Aguir F. 33
Akasbi M. 37, 41, 46
Akpek E.K. 17
Alarcón-Riquelme M.E. 31, 33
Alessandrova E. 35
Alessandri C. 41
Alevizos I. 25
Alivernini S. 35, 47
Allenbach Y. 40
Alochio L.V. 42
Altingöz E.N. 39
Altoé L.B. 42
Alunno A. 41
Alves Ribeiro L. 40
Anaya Cabrera J.M. 16
Andronikou V. 33
Antonopoulou K. 47
Appel S. 28, 32
Appenzeller S. 46
Aqrawi A.L. 29
Aradi Z. 40, 46
Arca K. 39, 41
Arends S. 20, 36, 39, 45
Armagan B. 37, 44, 46
Asam S. 32
Atoe A. 29
Avey S. 34
Axtell R.C. 38
B
Baer A. 11, 17, 45, 47
Baert-Jansen A. 47
Bagacean C. 28
Baker J. 36
Baker M.C. 42
Baldini C. 11, 13, 20, 24, 28, 33, 35, 37, 41, 46
Bandeira M. 32, 38, 41
Barath S. 43
Barbati C. 30, 42
Barbosa Beloni Lírio M. 43
Barnes M. 14
Barone F. 32
Baron G. 39
Barrio Cortes J. 17, 20
Bartels C. 40
Bartoloni Bocci E. 18, 28, 33, 41, 46
Basiaga M.L. 46
Batani V. 37
Beach M. 45
Bechara R. 29
Bekker C. 28
Bellone M. 37
Benveniste O. 40
Ben-Youssef A. 36, 37
Berardicurti O. 32
Berg M. 28
Bergum B. 28
Berhanu A. 44
Bhana S. 44
Bharaj T. 28
Bhaskaran S. 47
Bialkowski S. 32
Bianconi V. 28
Bikker F. 30
Bisaralli R. 36
Bisaroall R. 36
Blake W. 10
Blanchet O. 30
Blanc J. 47
Bloch D. 42
Blokland S. 28, 45
Boggio C. 45
Bombari M. 9, 33, 39, 45
Bombari S. 8, 20
Bonelli F. 37
Bonet D. 34
Boni A. 32
Bootsma H. 12, 14, 28, 29, 30, 31, 33, 36, 37, 39, 43, 45, 46
Borda Samper C. 39
Bordron A. 28
Borg H. 28, 29
Boulouet C. 47
Bowman S.J. 20, 29, 31, 32, 33, 39, 45
Bracciaia C. 32
Brahim L. 36
Brennan M. 31, 45
Brith B. 32
Brito I. 33
Brito-Zerón P. 17, 19, 37, 41, 44, 46
Brookland K. 28
Bromer J. 40
Brun J.G. 28, 32
Bruno D. 35
Bruunvoort C. 29, 31
Bryn G.A.W. 24, 38
Buckley C.D. 32
Bueno I.B. 38
Bugan A. 46
Buonocore G. 30, 42
Burmeister J. 33
Butt M. 30
C
Cafaro G. 15, 28
Ciappiello I. 32
Campbell K. 44
Camus M. 39
Capacci A. 44, 47
Carmona L. 44
Carretta R.Y.D. 43
Carsons S.E. 42
Carteron N.L. 42
Carubbi F. 37, 41, 44, 46
Carvajal Alegria G. 36, 37, 47
Cathleen P. 31
Cavett J. 29, 31
Celia A.I. 41
Chabrun F. 30
Chakraborty S. 41
Chaltsev B. 34, 35, 39, 44
Chambers A. 31
Chao De La Barca J. 30
Cha S. 46
Chatzis L. 12, 13, 31, 33, 35
Chevet B. 45
Chiara B. 40
Chiche L. 45
Chiorini J. 45
Chivasso C. 28
Chondrogiannis E. 33
Chouhan S. 36
Chowdhury F. 45
Chriti N. 39
Church J.E. 47
Cimsit C. 38
Cimsit C. 38
Cintra B.C. 43
Cirnir C. 29, 30
Cochener B. 37
Cochner-Lamard B. 36
Cofalzasshiac S. 10, 19, 30, 32, 33, 38, 41, 42
Cole J. 41
Conrad L. 28
Consani C. 37
Consani S. 46
Conti F. 17, 30, 38, 41, 42
Conze P. 36
Cornec D. 28, 30, 33, 36, 37, 39, 40, 45, 47
Cosentini E. 28
Courtosis-Communier E. 40
Coutinho G. 38
Cox R. 28
Croft A.P. 32
Curcio G. 42
D
Dagn A. 33
D’Agostino C. 28
D’Agostino M. 38, 44, 47
Danda D. 37, 46  
Danielides S. 42  
Davies R. 32  
De Benedetti F. 32  
Debo A. 42  
Depaco C. 24  
Delli K. 24, 36  
Del Papa N. 16  
Delporte C. 28, 33  
De Marchi G. 40, 41  
Depinay T. 47  
Desmoulins F. 30, 36  
De Souza E. 42  
De Souza V. A. 43  
Desvaux E. 13  
Devisscher-Pensec D. 37  
Devisscher-Pensec V. 28, 30, 33, 34, 36, 39, 41, 46, 47  
De Vita S. 8, 12, 17, 32, 33, 34, 35, 38, 40, 41  
De Wolff L. 36, 39, 43, 45  
Diaz M.C. 39, 43  
Di Franco M. 42  
Diilanni J. 46  
Direnzo D. 36  
Direskeneli H. 39  
Dizon B.L. 46  
Donati V. 33, 35  
Dongre H. 29  
Dong X. 37, 46  
Doria A. 16  
Dörner T. 12, 16, 19, 29, 33  
Dreher M. 32  
Dubost J.J. 34  
Dueymes M. 28, 33  
Duffau P. 40  
Dulin M. 10  
E  
Edens C. 46  
Elefante E. 33, 40  
El Zawahry O. 42  
Emery P. 45  
Erol Kalkan K. 38  
Esposito A. 40  
Estes J. 36  
Estevan Marques R. 38  
Eurico Fonseca J. 32  
Exarchos T.P. 14, 33, 35  
F  
Fabro C. 32, 35, 41  
Fonin R. 35  
Fonny Horváth I. 46  
Forris A.D. 31, 38, 44, 46  
Favorato L.F. 42  
Feijoo-Masso C. 41  
Fenando A. 36  
Fernández Ávila D.G. 39, 43  
Ferraccioli G. 12, 35  
Ferrari G. 37  
Ferreira G.A. 43  
Ferro R. 24, 33, 35, 36  
Filer A. 32  
Filipovic N. 28, 33  
Fisher B.A. 11, 32, 36, 39  
Flint J. 32  
Flores-Chavez A. 37, 41, 44, 46  
Florian K. 32  
Fonseca-Aizpuru E. 37, 46  
Fonseca J.E. 38, 40  
Fonzetti S. 33  
Fortune F. 39  
Fotiadis D.I. 14, 33, 35  
Fowler B. 46  
Fox R.I. 18, 42  
Franks C. 34  
Fremond G. 18  
Fromreide S. 28, 29  
Fulvio G. 36  
G  
Gaffney P. 29, 31  
Gaiduk I. 35  
Galisteo C. 37, 46  
Gallay L. 40  
Galli M. 19  
Galtung H. 29  
Gandolfo S. 33  
Garcia Alfonso C. 43  
Gardner D.H. 32  
Gauthier A. 24, 30, 38, 41, 42  
Georgel L. 37  
Georgescu C. 38  
Gervis P. 39  
Gerd R. 8, 16, 28, 33, 37, 41  
Gheita T.A. 37, 46  
Giacomelli R. 33, 37, 41, 46  
Gianfrancesco M. 44  
Gianoldi A.P.E. 42  
Giardina F. 30, 38, 41, 42  
Gioia C. 42  
Giovannini I. 24, 32, 34, 35, 38, 40  
Gomes M.D.P. 43  
Gonçalves A.I. 38  
Gonçalves M.L. 38  
Gonçalves Rodrigues De Aguiar L. 43  
González García A. 37, 46  
González Rojas B.J. 39  
Goodman B. 39, 41, 42  
Gordeev A. 36  
Gore-Massey M. 44  
Gorodetskiy V. 35  
Gossec L. 44  
Gottenberg J.E. 11, 34, 37, 39, 46  
Goules A.V. 11, 13, 14, 21, 31, 33, 35  
Grainger R. 44  
Grasland A. 40  
Grañé M. 37  
Gremer C. 35  
Grigoriadou S. 45  
Grissius M. 45  
Grosjean A. 47  
Grundahl K. 44, 46  
Guellec D. 36, 37, 40, 47  
Gupta S. 45  
Guthridge J. 38  
Gutierrez Davila J.M. 39  
Gutierrez J.M. 43  
H  
Hachulla E. 34, 40  
Hakan E. 38  
Hamkour S. 19, 45  
Hammenfors D. 32, 36  
Hammitt K.M. 20, 42, 44, 45, 47  
Han J.H. 36  
Hanova P. 38  
Harris-Lewis V. 31  
Hassanein D. 42  
Hausmann J.S. 44  
Hayem G. 40  
Heldesen Y. 28  
Heldesen Y. 28  
Hemon P. 31, 37  
Hernandez-Molina G. 37, 41, 46  
Hetzel S. 40  
Higham J. 32  
Hillen M. 28  
Hillion S. 30  
Hinrichs A. 28, 30  
Hjertviken Lindland A. 47  
Hocevar A. 24, 34, 38  
Hofauer B. 36, 37, 41, 46  
Hoffman R.W. 44  
Hofland I. 30  
Holley A. 42  
Hou X. 34  
Hyrich K. 44  
I  
lagnocchi A. 38  
Iannizzotto V. 32  
Iannuccelli C. 42  
Ilgen U. 38
Illei G. 20
Inanc N. 19, 37, 38, 39, 41, 46
Inoue Sato E. 43
Isenberg D. 37, 46
Isola M. 35
Izzo R. 30, 38, 41, 42

J
Jabari D. 36
Jacobsohn L. 44
James J.A. 29, 31, 38
Jason D.T. 32
Ji Y. 45
Joachims M. 29, 31, 46

K
Kachaner A. 36
Kalatzis F. 33
Kapsogeorgou E. 9
Kapuruz A. 39
Karacayli U. 39
Karanastasis E. 33
Kassapidis P. 31
Keen H. 38
Khatri B. 29, 31, 38
Khavandgar Z. 45
Khmelinskii N. 32, 38
Khouri Z. 45
Khvam Y. 34, 35, 39, 44
Kim H. 36
Kim J. 36
Koelewijn-Tukker J. 47
Koelsch K.A. 29, 31, 38
Kokosadze N. 35
Kolijn P.M. 34
Kostov B. 44
Kourou D.K. 33
Kroese F.G.M. 9, 28, 29, 30, 31, 36, 43
Kruize A. 28, 30, 37, 46
Kurien B. 29, 31
Kurien B.T. 31
Kvarnstrom M. 37, 46
Kwok S. 37, 46

L
Labetoulle M. 37
Lafeber F. 28, 30
Lai W. 41
Laing Gibbard L. 43
Lamard M. 36
Lamotte C. 36
Lançã M. 38
Langerak A.W. 34
Lang S. 41
La Rocca G. 33
Larroche C. 34
Lavigne C. 30, 34
Law B. 12
Lawrence C. 38
Lawrence S. 31
Lawson-Tovey S. 44
Lee H. 28, 30, 45
Lee J. 36, 43
Le Guerri N. 31, 40
Le Guern L. 30
Le Guern V. 34, 40
Lessard C.J. 9, 10, 15, 21, 29, 31, 38, 44, 46
Leszczuk J. 34
Letourneur F. 28
Leu J.H. 44
Lewis M. 45
Lewis V. 31
Liaaen Jensen J. 29
Libardi Lira Machado K.L. 43
Li C. 37, 46
Lieberman S.M. 46
Liefer S.C. 29
Liew J.W. 44
Ling L.E. 44
Lino A. 29
Lischchuk L. 33
Liu G. 34
Liva S.G. 44
Li X. 37, 46
Lizano M. 31
Lo K.H. 44
Longhino S. 32, 33, 35, 38, 40, 41
Longobardi S. 38
Lontoc T. 34
Lopes A. 28
Lopes P. 38
Lopez-Davis C. 38
López-Dupla M. 37, 41, 46
Lorenzon M. 24
Lozac H.P. 30
Lucchesi D. 45
Luczak A. 30

M
Machado K.L.L. 42
Machado P.M. 44
Macieira C. 38
Mackey A. 47
Madej M. 30
Makara M. 42, 44, 45, 47
Mancini P. 42
Mandel S. 42
Manfré V. 15, 32, 33, 34, 35, 38, 40, 41
Mannarino M.R. 28
Manousakis M. 13
Marasco E. 32
Marcelli C. 34
Marcorèlles P. 47
Marec N. 30
Marhadour T. 37, 40, 47
Mariampillai K. 40
Mariani L. 42
Mariette X. 12, 21, 28, 29, 30, 31, 34, 36, 39, 40, 41
Marinoska T. 32
Marrani E. 18
Martin-Gutierrez L. 29, 30
Martins A.L. 38
Martis N. 40
Marzola M.M. 43
Masaoutis C. 35
Mastromonaco L. 30, 38, 41, 42
Matheus E.F. 44
Matianova E. 41
Matteo V. 32
Mattii L. 28
Mavragani C. 14
Mavragani P.C. 33
May T. 33
McCoy S. 40
McCoy S. 15
Medeiros J. 40
Melchor Díaz S. 46
Melchor Díaz S. 37
Melchor S. 44
Meyer A. 40
Milic V. 36
Mill J.G. 43
Miyamoto S.T. 42
Moawad P. 42
Moça Trevisani V. 37, 46
Mückel T. 32
Módis L. 46
Monticello O.A. 43
Morel J. 37, 46
Morel M. 28
Morena Bueno Silva L. 38
Moroni L. 37
Morris M. 34
Mosca K. 34
Mosca M. 18, 21, 33
Moscati S. 28
Mossel E. 36
Mota J.C. 42
Mougeot F. 31
Mougeot J. 31
Mourits M. 31
Mouterde G. 36  
Moutsopoulos H.M. 33, 35  
Muhammad S.S. 28  
Mulleman D. 40  
Mumcu G. 38, 39  
Murphy P. 34  

Nagel A. 29, 31  
Nagy B. 43  
Nagy G. 40  
Nakshbandi U. 29  
Nanda R. 36  
Napenas J. 45  
Naredo E. 38  
Narovini L. 24  
Narvarrete Motta L.E. 39, 43  
Narvarro Garcia I.C. 33  
Navarro I. 33, 40  
Nayar S. 16, 32  
Nettey O. 29  
Neves Burian A.P. 43  
Nguyen C. 19, 31, 45  
Ng W.F. 14, 29, 31, 32, 33, 37, 41, 45, 46  
Nicolai R. 32  
Nicole N.R.S. 42  
Nimwegen J. 31  
Noaiseh G. 36, 42  
Nocturne G. 9, 16, 28, 29, 30, 34, 36, 40  
Noll B. 31  
Noll J. 31, 45  
Nordmark G. 29, 31, 37, 46  
Noronha B.D. 42  
Noury J. 40  
Novikov A. 35, 36  

Olie L. 36  
Oliveira F.R. 38, 42, 43  
Oliveira M.C. 38  
Oliveira Souza B. 43  
Olsson P. 37, 46  
Omdal R. 29, 31  
Oosterbaan M. 47  
Orlandi M. 41  
Orosz V. 40, 43  
Orrock J.E. 46  
Ozkiziltas B. 37, 46  

Paglionico A. 35  
Pagni S. 44, 45  
Palshino S. 35, 36  
Pandis I. 34  
Pandit A. 28  
Papas A. 15, 41, 44, 45  
Paprovnik S. 37, 46  
Paraskevi V. 35  
Pardo G. 38  
Parisis D. 33  
Park A. 42  
Pascoud J. 28, 29  
Pasoto S.G. 37, 41, 46  
Patel C. 34  
Pavlakis P.P. 42  
Peckham H. 29  
Pedrini A.P.T. 42  
Pegolo E. 32, 35  
Pelayo E. 45  
Peng J. 29, 30  
Pérez M.M. 33  
Perez P. 45  
Perret J. 28  
Perricone C. 28  
Perrodeau E. 39  
Pers J.O. 11, 21, 28, 30, 31, 37, 39, 47  
Petrovic A. 32  
Pezoulas V.C. 33, 35  
Pharaoh G. 31  
Pincemin M. 47  
Pineda C. 38  
Pinheiro Lopes A. 10  
Pinto J. 38  
Pires Marafon D. 32  
Pirro M. 28  
Pitzalis C. 45  
Pochard P. 28  
Pontarini E. 45  
Ponzoni M. 8, 35  
Porcher R. 39, 45  
Porchet E. 30  
Pors V. 47  
Portanova G. 42  
Poveda-Gallego A. 32  
Pranzatelli T. 45  
Principe G. 32  
Pringle S. 28, 29, 30  
Priori R. 18, 30, 33, 37, 38, 41, 42, 44, 46  
Probota V. 35  
Pucino V. 32  
Purdie J. 45  

Quartuccio L. 14, 19, 32, 33, 34, 35, 37, 40, 41, 46  
Quellec G. 36  
Quéré B. 16, 36, 40  

Rabaut R. 40  
Rafdar L. 29, 31, 38, 44  
Radic M. 18  
Radstake T. 28  
Radziszewska A. 29  
Radziszewski M. 31  
Ragab G. 42  
Rajão Martins F. 33  
Ramirez J. 43  
Ramos-Casals M. 20, 21, 33, 37, 41, 44, 47  
Randell R. 46  
Rasmussen A. 29, 31, 37, 38, 44, 46  
Rath P.D. 36  
Rauz S. 32  
Reed J. 12  
Reis Neto E. 43  
Retamozo S. 17, 19, 37, 41, 46  
Reynier P. 30  
Reynoso E. 34  
Ribeiro Moulaz I. 43  
Ricci F. 44  
Riccucci I. 28  
Richards A. 32  
Rischmuller M. 29, 31, 37, 46  
Ritter J. 29  
Rivellese F. 45  
Rivière E. 28, 29  
Rizzo M.T. 32, 33, 35, 41  
Robinson G. 30  
Robles A. 41  
Rocca J. 34  
Rocha E.M. 43  
Rodionova E. 35, 36  
Rodrigues M. 33  
Rodrigues W. 38  
Roh J. 36  
Romão V.C. 32, 37, 38, 40, 41, 44, 46  
Rönnblom L. 29, 31  
Rontogianni D. 35  
Roorn J.V. 39  
Rosa B.B. 42  
Rubortane P. 44, 47  
Rusbuldt J. 46  

Safonova T. 35  
Sahu A.K. 36  
Salvado F. 38  
Salviato Pillegi G. 43  
Sánchez-Berná I. 37, 46  
Sandhya P. 33  
Sanges S. 40  
Sankar V. 44, 45  
Santos P.H.A. 42  
Saraux A. 33, 36, 37, 40, 47  
Sarka G. 42  
Sarkar I. 32  
Sarzi Puttini P. 18  
Sawicki B. 41  
Schaefer M. 44  
Schmidt J. 34
Schmidt W.A. 38
Schrezenmeier E. 29
Schwarting A. 32
Sciaccia E. 45
Scofield R.H. 29, 31, 38, 42, 44, 46
Scott C.A. 35
Scuiller Y. 31, 37
Sebastian A. 30, 37, 46
Sebastian M. 30
Seghieri C. 20
Sene D. 37, 46
Serrairollo R. 14, 30, 34, 36, 37, 39, 41, 44, 45, 46
Serraino D. 34
Serrano É.V. 42
Shahnawaz Soyfoo M. 33
Shah S. 36
Shalabi H. 29
Shamma R. 42
Shiboski C.H. 20, 21
Shimizu T. 37, 46
Shornikova L. 28, 29
Shornikova N. 35
Silvério António M. 38
Simão R. 38
Simard G. 30
Simoncelli E. 30, 38, 41, 42
Singh M. 41, 44, 45
Sirotich E. 44
Sivils K. 25, 29, 31, 33, 44, 46
Sivils K.L. 46
Skarstein K. 28, 29
Skopouli F. 33, 35
Smith C. 32
Smith Sobral Vieira G. 43
Smolenska A. 31
Solberg S.M. 32
Spikervet F. 28
Srivastava K. 29
Stanislawski A. 29
Steinmetz T. 43
Steketee R.W. 29
Stephens C. 45
Stergiou I. 35
Stern S.M. 46
Stevens A.M. 44
Stolarczyk A. 29, 31
Stone L. 47
Strangfeld A. 44
Suklja P. 44
Sung-Eun C. 36
Sutcliffe N. 45
Suzuki Y. 37, 46
Szántó A. 37, 40, 43, 46
Szelinska F. 29
Taborelli M. 34
Tappuni A. 45
Tatami Miyamoto S. 43
Tautila I. 39
Taylor J.K. 10
Taylor Y. 45
Teixeira-Carvalho A. 43
Teodósio A. 32
Terpstra J. 43
Terslev L. 38
Tessneer K. 29, 31
Thatayatikom A. 46
Thornburg T. 31
Tiger S. 46
Tison A. 30, 33, 40
Toffolotti F. 34
Tolusso B. 35
Tomé W.A. 42
Tommasini A. 17
Torgashina A. 34, 35, 39, 41, 44
Tornaas S. 28
Torsten W. 33
Treemarcki E.B. 46
Treppe E. 34, 40
Tsalka M. 29
Tsao B. 29
Tsiknakis M. 33
Türe-Özdemir F. 39
Turner B. 47
Turner J.D. 32
Tzioufas A.G. 11, 12, 17, 21, 31, 33, 35
Urbanski G. 11, 30
Valim V. 37, 42, 43, 44, 46
Valstar M. 30
Van Daele P.L. 34
Van Der Tuuk K. 31
Van Der Vegt B. 29, 30
Van Ginkel M.S. 29
Van Helden-Meeuwsen C.G. 34
Van Kempen L. 31
Van Nimwegen J. 36
Van Roon J. 28, 30, 33, 45
Van wormer J. 40
Van Zuiden G. 36
Varadachary A. 42
Varriano V. 33
Vasiliev V. 34, 35, 36, 44
Vázquez M. 37, 46
Venetsanopoulou A. 33
Ven K. 34
Verizhnikova Z. 34
Vermeulen A. 44
Versnel M.A. 9, 34, 45
Verstappen G. 31, 36, 43
Verstappen G.M. 9
Vieira A. 20, 47
Vieira Serrano É. 43
Villa M. 30, 38, 41, 42
Visser A. 31, 43
Visser-Noordegraaf M. 47
Vissink A. 11, 28, 29, 30, 36
Vitale C. 19
Vittecaq O. 34
Vogel W. 30
Voigt A. 31
Votis K. 33
Voulgarelis H. 12
Voulgarelis M. 35
Wahadat M.J. 34
Wahren-Herlenius M. 29, 31
Wallace D.J. 42, 44
Wallace Z. 44
Warner B. 29, 31, 45
Wharen-Herlenius M. 9
Wiland P. 30
Wiley M. 29, 31
Witte T. 9, 29, 31
Wren J.D. 38
Xavier M. 33, 45
Xavier R. 43
Yarowsky D. 47
Yazdany J. 44
Yenisoy Y. 39
Yu S. 41
Zabotti A. 11, 12, 24, 32, 34, 35, 38, 40
Zaja F. 35
Zampelli E. 33
Zandonella Callegher S. 38
Zazzetti F. 44
Zemelka-Wiacek M. 30
Zeng W. 13
Zhang S. 30
Zindy E. 28
Zuraw Q. 44
SPONSORS ACKNOWLEDGEMENT

Platinum Sponsor

HORIZON.

Gold Sponsors

Bristol Myers Squibb

NOVARTIS

Silver Sponsor

Janssen

Supporters

ALFASIGMA

esaote
15th
SEPTEMBER
2022
ROME

INTERNATIONAL SYMPOSIUM ON
Sjögren’s Syndrome

ORGANIZING SECRETARIAT

AIM Group International – Milan Office
Via G. Ripamonti, 129 – 20141 Milan, Italy
Info: sjögren2022@aimgroup.eu
Registrations: sjögren2022.reg@aimgroup.eu
Abstract: sjögren2022.abs@aimgroup.eu